mitomycin has been researched along with Carcinoma, Anaplastic in 207 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our goal was to evaluate long-term safety and durability of response to UGN-101, a mitomycin-containing reverse thermal gel, as primary chemoablative treatment for low-grade upper tract urothelial carcinoma." | 9.51 | Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report. ( Chamie, K; Coleman, J; Godoy, G; Gore, JL; Hakim, G; Hu, B; Hubosky, SG; Humphreys, MR; Kaimakliotis, H; Klein, I; Kleinmann, N; Knoedler, JJ; Konorty, M; Lerner, SP; Lifshitz, D; Linehan, J; Matin, SF; O'Donnell, M; Pak, R; Pierorazio, PM; Quek, M; Raman, JD; Rivera, M; Scherr, D; Schoenberg, M; Seltzer, E; Shabsigh, A; Smith, AB; Strauss-Ayali, D; Verni, M; Weight, C; Weizer, A; Woods, M, 2022) |
| "This prospective study aimed to evaluate the feasibility and safety of locoregional mitomycin C (MMC) injection to treat refractory esophageal strictures after endoscopic submucosal dissection (ESD) for superficial esophageal carcinoma." | 9.16 | Locoregional mitomycin C injection for esophageal stricture after endoscopic submucosal dissection. ( Arakawa, T; Fujiwara, Y; Machida, H; Minamino, H; Okazaki, H; Sugimori, S; Tanigawa, T; Tominaga, K; Watanabe, K; Watanabe, T; Yamagami, H, 2012) |
| " Our aim was to compare TURBT alone with immediate post-TURBT intravesical passive diffusion (PD) of mitomycin and immediate pre-TURBT intravesical electromotive drug administration (EMDA) of mitomycin in non-muscle invasive bladder cancer." | 9.15 | Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. ( Di Stasi, SM; Giurioli, A; Leprini, G; Liberati, E; Masedu, F; Micali, F; Ricci, AR; Valenti, M; Verri, C; Vespasiani, G, 2011) |
| "Combining radiation with mitomycin and cisplatin in patients with locally advanced anal cancer is feasible." | 9.12 | Combining cisplatin and mitomycin with radiotherapy in anal carcinoma. ( Bosset, JF; Bosset, M; Buffet-Miny, J; Crehange, G; Dumas, JL; Lorchel, F; Mercier, M; Puyraveau, M, 2007) |
| "Aim of this study was to evaluate the activity of a combination regimen of chemotherapy containing mitomycin C (MMC) and etoposide (ETO) in advanced colorectal carcinoma." | 9.12 | Mitomycin C and etoposide in advanced colorectal carcinoma. A clinical and in vitro experience that focuses the problem of schedule dependence in combination therapy. ( Cicconetti, F; Franchi, F; Iascone, C; Ielapi, T; Nigita, G; Pastore, C; Seminara, P, 2007) |
| "A prospective Phase II trial was carried out with 83 patients who had digestive tract cancer and peritoneal carcinomatosis to evaluate the tolerance and efficacy of IPCH with mitomycin C (MMC) associated with surgery." | 9.09 | Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis. ( Beaujard, AC; Bienvenu, J; Caillot, JL; Francois, Y; Garbit, F; Gilly, FN; Glehen, O; Grandclément, E; Panteix, G; Vignal, J, 2000) |
| "Forty patients with anthracycline pretreated metastatic breast cancer were treated with a combination of mitomycin C 10 mg/m2 i." | 9.07 | Mitomycin "C" and vinorelbine as second line chemotherapy for metastatic breast carcinoma. ( Agostara, B; Callari, AM; Cusimano, MP; Gebbia, N; Gebbia, V; Testa, A, 1994) |
| "Based on a recent pharmacokinetic study suggesting that high biliary levels of mitomycin C (MMC) may be achieved as a result of an entero-hepatic recycling mechanism, we conducted a Phase II EORTC trial which involved MMC administration to patients with non-resectable biliary tract carcinoma." | 9.07 | Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group Study. ( Audisio, RA; Bleiberg, H; Blijham, GH; Duez, N; Neijt, JP; Sahmoud, T; Taal, BG; Veenhof, CH, 1993) |
| "One hundred forty-two patients with progressive, hormonally refractory advanced prostate carcinoma who had not received prior chemotherapy were randomized to receive either combination chemotherapy with 5-fluorouracil (5-FU), doxorubicin, and mitomycin C (FAM) or sequential chemotherapy with the same agents, i." | 9.07 | Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil. ( Hahn, RG; Krook, JE; Laurie, JA; Mailliard, JA; Morton, RF; Patel, SR; Therneau, TM; Twito, DI; Windschitl, HE, 1992) |
| "Fifty-five patients with metastatic carcinomas of unknown primary site (50 adenocarcinomas) were randomized, after stratification, to treatment with either mitomycin and doxorubicin (MA) or mitomycin, doxorubicin, and cisplatin (MAP)." | 9.06 | Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. A randomized trial. ( Eagan, RT; Long, HJ; Rubin, J; Schutt, AJ; Therneau, TM, 1987) |
| "To investigate the effects of mitomycin-C (MMC) and 5-fluorouracil (5-FU) on the viability, proliferation, and migratory capacity of cultured ocular adnexal sebaceous carcinoma (SC) cells." | 8.12 | Effects of Mitomycin-C and 5-Fluorouracil on Ocular Adnexal Sebaceous Carcinoma Cells. ( Gallo, RA; Gomez, A; Lang, SH; Pelaez, D; Rong, AJ; Sabater, AL; Tse, DT, 2022) |
| " The aim of this study was to investigate the inhibitory effects of mitomycin C (MMC) combined with a novel antibody fragment (Fab) targeting latent membrane protein 1 (LMP1) on nasopharyngeal carcinoma (NPC) xenograft nude mice." | 7.78 | A novel LMP1 antibody synergizes with mitomycin C to inhibit nasopharyngeal carcinoma growth in vivo through inducing apoptosis and downregulating vascular endothelial growth factor. ( Cao, Q; Chen, RJ; Feng, ZQ; Mao, Y; Wen, J; Zhang, DW; Zhu, J, 2012) |
| "The patients included were 145 who had colorectal or appendiceal carcinomatosis resected using cytoreductive surgery prior to treatment with hyperthermic intraperitoneal chemotherapy with mitomycin C as part of a multidrug regimen." | 7.77 | Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis. ( Chang, D; Mahteme, H; Stuart, OA; Sugarbaker, PH; Van der Speeten, K, 2011) |
| "To report the effect of regional combination chemotherapy in a cohort of patients with inoperable pancreatic carcinoma treated with or without low-dose warfarin." | 7.73 | Effects of low-dose warfarin and regional chemotherapy on survival in patients with pancreatic carcinoma. ( Löhr, M; Müller, H; Nakchbandi, IA; Nakchbandi, W; Singer, MV, 2006) |
| "We performed a retrospective chart review of a prospective database for patients undergoing CS and IPHC with mitomycin C for peritoneal carcinomatosis from colorectal primary lesions between December 1991 and April 2002." | 7.72 | Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. ( Fleming, RA; Geisinger, KR; Hawksworth, J; Levine, EA; Loggie, BW; Lovato, J; Shen, P, 2004) |
| "This study describes characteristics of a human bladder cancer cell line J82/MMC that is 6-fold more resistant to mitomycin C (MMC) than the parental cells." | 7.69 | Characterization of a human bladder cancer cell line selected for resistance to mitomycin C. ( Gupta, V; Singh, SV; Xu, BH, 1994) |
| "The intensity of lymphoid cell infiltration and distribution of lymphocyte subsets in tumors were investigated immunohistochemically on tumor tissues obtained from 11 patients with gastric carcinoma, who had been treated with mitomycin C (MMC), 12 mg/m2, i." | 7.68 | Immunohistochemical analysis of lymphocyte subsets infiltrating gastric carcinoma after mitomycin C administration. ( Adachi, M; Akiyoshi, T; Arinaga, S; Inoue, H; Karimine, N; Korenaga, D; Ueo, H, 1992) |
| "We analyzed 29 cases of eosinophilic cystitis in a group of 80 patients with lower urothelial carcinoma who had been treated with mitomycin-C." | 7.68 | [Eosinophilic cystitis as a special form of response to mitomycin C. Analysis and comments on our cases]. ( Arango Toro, O; Bielsa Galí, O; Corominas, J; Gelabert Mas, A; Lladó Carbonell, C; Vesa Llanes, J, 1991) |
| "We retrospectively examined the long-term results of adjuvant chemotherapy with mitomycin-C (MMC) in 50 patients with gastric carcinoma invading the adjacent organs." | 7.68 | Adjuvant mitomycin-C prolongs survival time of patients undergoing extensive en bloc resection of carcinoma of the stomach invading the adjacent organs. ( Baba, H; Haraguchi, M; Kakeji, Y; Korenaga, D; Maehara, Y; Orita, H; Sugimachi, K; Watanabe, A, 1990) |
| "The disposition kinetics of the cancer chemotherapeutic agent mitomycin C have been studied in six male patients receiving mitomycin C in combination with cisplatin and vinblastine for non-oat cell carcinoma of the lung." | 7.67 | Pharmacokinetics of mitomycin C in non-oat cell carcinoma of the lung. ( Buice, RG; Gurley, BJ; Niell, HB; Sidhu, P, 1984) |
| " We determined the increase in antineoplastic activities of mitomycin C (MMC) and carboquone (CQ) against human tumor cells under conditions of in vitro hypoxia, with the following results." | 7.67 | Hypoxia enhances the lethality of mitomycin C and carboquone against human malignant tumor cells in vitro. ( Kusumoto, T; Maehara, Y; Sakaguchi, Y; Saku, M; Sugimachi, K, 1989) |
| "KW 2083, which is a new mitomycin C derivative currently under clinical investigation, was tested for its antitumor effect on the growth of human carcinoma of the lung by using an in vitro clonogenic assay system." | 7.67 | Evaluation of a new drug 7-N-(p-hydroxyphenyl)-mitomycin C [KW 2083] against carcinoma of the lung by the human tumor clonogenic assay. ( Hoshi, A; Kanzawa, F; Matsushima, Y; Miyazawa, N; Saijo, N; Shimizu, E, 1985) |
| " Patients (aged ≥18 years) with primary or recurrent biopsy-proven, low-grade upper tract urothelial cancer (measuring 5-15 mm in maximum diameter) and an Eastern Cooperative Oncology Group performance status score of less than 3 (Karnofsky Performance Status score >40) were registered to receive six instillations of once-weekly UGN-101 (mitomycin 4 mg per mL; dosed according to volume of patient's renal pelvis and calyces, maximum 60 mg per instillation) via retrograde catheter to the renal pelvis and calyces." | 6.94 | Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. ( Adibi, M; Amin, MB; Chamie, K; Coleman, J; Godoy, G; Gore, JL; Hakim, G; Hu, B; Hubosky, S; Humphreys, MR; Kaimakliotis, H; Klein, I; Kleinmann, N; Knoedler, JJ; Konorty, M; Lerner, SP; Lifshitz, D; Linehan, J; Matin, SF; O'Donnell, M; Pak, R; Pierorazio, PM; Quek, M; Raman, JD; Rivera, M; Scherr, D; Schoenberg, M; Seltzer, E; Shabsigh, A; Smith, AB; Stern, J; Strauss-Ayali, D; Verni, M; Weight, C; Weizer, A; Woods, M, 2020) |
| "Patients with peritoneal carcinomatosis have a uniformly poor prognosis." | 6.71 | Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. ( Case, D; Fleming, R; Geisinger, KR; Hall, J; Levine, EA; Loggie, BW; McQuellon, R; Russell, G; Shen, P, 2003) |
| "Forty patients with locally advanced cervical carcinoma were entered into a protocol utilizing the bolus administration of both mitomycin C (10 or 15 mg) on Day 1 and 5-fluorouracil (400 mg) on Day 1-5 followed by sequential pelvic irradiation on Day 6 between September 1980 and October 1985." | 6.18 | Bolus mitomycin C and 5-FU with sequential radiation for poor-prognosis locally advanced cervical cancer. ( Breen, JL; Denehy, TR; Eastman, R; Gregori, CA; SanFilippo, L, 1996) |
| "Our goal was to evaluate long-term safety and durability of response to UGN-101, a mitomycin-containing reverse thermal gel, as primary chemoablative treatment for low-grade upper tract urothelial carcinoma." | 5.51 | Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report. ( Chamie, K; Coleman, J; Godoy, G; Gore, JL; Hakim, G; Hu, B; Hubosky, SG; Humphreys, MR; Kaimakliotis, H; Klein, I; Kleinmann, N; Knoedler, JJ; Konorty, M; Lerner, SP; Lifshitz, D; Linehan, J; Matin, SF; O'Donnell, M; Pak, R; Pierorazio, PM; Quek, M; Raman, JD; Rivera, M; Scherr, D; Schoenberg, M; Seltzer, E; Shabsigh, A; Smith, AB; Strauss-Ayali, D; Verni, M; Weight, C; Weizer, A; Woods, M, 2022) |
| "Colorectal peritoneal carcinomatosis (PC) is commonly treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)." | 5.48 | Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC. ( Aalbers, AGJ; Boot, H; Huitema, ADR; Kok, NFM; van Eden, WJ; Woensdregt, K, 2018) |
| "We report on a 45-year-old breast cancer patient with disseminated hepatic metastases." | 5.36 | Successful remission of extensive liver metastases in a breast cancer patient with acute liver failure using a combined chemotherapy regimen with mitomycin, folinate, and 5-fluorouracil (Mi/Fo/FU). ( Eichbaum, MH; Hauser, N; Hohl, MK; Sohn, C; Stoiber, B; Stoiber, N, 2010) |
| "Mitomycin C was administered as a perfusate at 10 mg/l." | 5.32 | Treatment of peritoneal carcinomatosis in patients with digestive cancers with combination of intraperitoneal hyperthermia and mitomycin C. ( Banssillon, V; Bienvenu, J; Francois, Y; Garbit, F; Gilly, FN; Glehen, O; Grandclément, E; Panteix, G; Sadeghi-Looyeh, B; Sayag-Beaujard, AC; Vignal, J, 2004) |
| "Mitomycin C (10 mg/m2) was administered as a bolus injection on day 2." | 5.28 | Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma. ( Coia, LR; Engstrom, PF; Hanks, GE; Paul, AR; Stafford, PM, 1991) |
| "Persistent or recurrent peritoneal carcinomatosis (PC) documented at second-look surgery has proved relatively refractory to second-line therapy." | 5.27 | Intraperitoneal mitomycin C in the treatment of peritoneal carcinomatosis following second-look surgery. ( Alberts, DS; Graham, V; Monk, BJ; Surwit, EA, 1988) |
| "This prospective study aimed to evaluate the feasibility and safety of locoregional mitomycin C (MMC) injection to treat refractory esophageal strictures after endoscopic submucosal dissection (ESD) for superficial esophageal carcinoma." | 5.16 | Locoregional mitomycin C injection for esophageal stricture after endoscopic submucosal dissection. ( Arakawa, T; Fujiwara, Y; Machida, H; Minamino, H; Okazaki, H; Sugimori, S; Tanigawa, T; Tominaga, K; Watanabe, K; Watanabe, T; Yamagami, H, 2012) |
| " Our aim was to compare TURBT alone with immediate post-TURBT intravesical passive diffusion (PD) of mitomycin and immediate pre-TURBT intravesical electromotive drug administration (EMDA) of mitomycin in non-muscle invasive bladder cancer." | 5.15 | Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. ( Di Stasi, SM; Giurioli, A; Leprini, G; Liberati, E; Masedu, F; Micali, F; Ricci, AR; Valenti, M; Verri, C; Vespasiani, G, 2011) |
| "Combining radiation with mitomycin and cisplatin in patients with locally advanced anal cancer is feasible." | 5.12 | Combining cisplatin and mitomycin with radiotherapy in anal carcinoma. ( Bosset, JF; Bosset, M; Buffet-Miny, J; Crehange, G; Dumas, JL; Lorchel, F; Mercier, M; Puyraveau, M, 2007) |
| "Aim of this study was to evaluate the activity of a combination regimen of chemotherapy containing mitomycin C (MMC) and etoposide (ETO) in advanced colorectal carcinoma." | 5.12 | Mitomycin C and etoposide in advanced colorectal carcinoma. A clinical and in vitro experience that focuses the problem of schedule dependence in combination therapy. ( Cicconetti, F; Franchi, F; Iascone, C; Ielapi, T; Nigita, G; Pastore, C; Seminara, P, 2007) |
| "A prospective Phase II trial was carried out with 83 patients who had digestive tract cancer and peritoneal carcinomatosis to evaluate the tolerance and efficacy of IPCH with mitomycin C (MMC) associated with surgery." | 5.09 | Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis. ( Beaujard, AC; Bienvenu, J; Caillot, JL; Francois, Y; Garbit, F; Gilly, FN; Glehen, O; Grandclément, E; Panteix, G; Vignal, J, 2000) |
| "Between August 1990 and December 1997, 25 patients with stage III and IV nasopharyngeal carcinoma received an accelerated and hyperfractionated radiotherapy with concurrent chemotherapy (5-FU and mitomycin C)." | 5.09 | Accelerated hyperfractionated radiotherapy with concurrent chemotherapy in locally advanced nasopharyngeal carcinoma: a phase II study. ( Budach, V; Fischer, M; Jahnke, K; Klahold, M; Sack, H; Stüben, G; Stuschke, M, 2001) |
| "The combination of cisplatin, epirubicin, and leucovorin preceding fluorouracil (PELF) includes three novel agents compared with the standard combination of fluorouracil, doxorubicin, and mitomycin (FAM) in the treatment of advanced gastric carcinoma." | 5.07 | Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. ( Algeri, R; Bella, M; Cocconi, G; De Lisi, V; Di Costanzo, F; Luppi, G; Mazzocchi, B; Rodinò, C; Soldani, M; Zironi, S, 1994) |
| "Forty patients with anthracycline pretreated metastatic breast cancer were treated with a combination of mitomycin C 10 mg/m2 i." | 5.07 | Mitomycin "C" and vinorelbine as second line chemotherapy for metastatic breast carcinoma. ( Agostara, B; Callari, AM; Cusimano, MP; Gebbia, N; Gebbia, V; Testa, A, 1994) |
| "Based on a recent pharmacokinetic study suggesting that high biliary levels of mitomycin C (MMC) may be achieved as a result of an entero-hepatic recycling mechanism, we conducted a Phase II EORTC trial which involved MMC administration to patients with non-resectable biliary tract carcinoma." | 5.07 | Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group Study. ( Audisio, RA; Bleiberg, H; Blijham, GH; Duez, N; Neijt, JP; Sahmoud, T; Taal, BG; Veenhof, CH, 1993) |
| "One hundred forty-two patients with progressive, hormonally refractory advanced prostate carcinoma who had not received prior chemotherapy were randomized to receive either combination chemotherapy with 5-fluorouracil (5-FU), doxorubicin, and mitomycin C (FAM) or sequential chemotherapy with the same agents, i." | 5.07 | Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil. ( Hahn, RG; Krook, JE; Laurie, JA; Mailliard, JA; Morton, RF; Patel, SR; Therneau, TM; Twito, DI; Windschitl, HE, 1992) |
| "Fifty-five patients with metastatic carcinomas of unknown primary site (50 adenocarcinomas) were randomized, after stratification, to treatment with either mitomycin and doxorubicin (MA) or mitomycin, doxorubicin, and cisplatin (MAP)." | 5.06 | Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. A randomized trial. ( Eagan, RT; Long, HJ; Rubin, J; Schutt, AJ; Therneau, TM, 1987) |
| "Three hundred eligible patients with carcinoma of the cervix out of a total of 560, registered between July 1981 and June 1983 were randomized into receiving either radiotherapy alone or radiotherapy plus weekly injection of bleomycin 15 mg and mitomycin C4 mg." | 5.05 | Chemotherapy-radiotherapy combination in the treatment of carcinoma of the cervix. ( Dharmalingam, SK; Singh, P; Tan, CK; Tan, MK, 1985) |
| "To investigate the effects of mitomycin-C (MMC) and 5-fluorouracil (5-FU) on the viability, proliferation, and migratory capacity of cultured ocular adnexal sebaceous carcinoma (SC) cells." | 4.12 | Effects of Mitomycin-C and 5-Fluorouracil on Ocular Adnexal Sebaceous Carcinoma Cells. ( Gallo, RA; Gomez, A; Lang, SH; Pelaez, D; Rong, AJ; Sabater, AL; Tse, DT, 2022) |
| "During a regular MR control, the patient developed anaphylactic reaction to Gadolinium, and after that a rectosigmoid ischemia with total necrosis of the posterior rectal wall was diagnosed and surgically treated with Hartmann procedure." | 3.91 | Hypovolemic shock after pelvic radiotherapy. A rare combination leading to a devastating complication. ( Calvisi, G; Carlei, F; Di Sibio, A; Di Staso, M; Giuliani, A; Lombardi, L; Marchese, M; Romano, L; Romanzi, F; Schietroma, M, 2019) |
| " More than 50% of centers administer oxaliplatin (74%), or mitomycin-C (65%) in colorectal cancer; cisplatin in gastric cancer (73%) and mesothelioma (74%)." | 3.88 | Current practice in cytoreductive surgery and HIPEC for metastatic peritoneal disease: Spanish multicentric survey. ( Barrios, P; Cascales-Campos, P; Esteve-Pérez, N; Morales-Soriano, R; Segura-Sampedro, JJ, 2018) |
| " This study evaluated the growth inhibition of GFW using normal human urothelial cells and bladder cancer cells; the efficacy of GFW treatment was further compared with mitomycin C, epirubicin, and cisplatin." | 3.79 | The investigation of a traditional Chinese medicine, Guizhi Fuling Wan (GFW) as an intravesical therapeutic agent for urothelial carcinoma of the bladder. ( Chan, MW; Chen, LG; Chen, SY; Hsieh, HY; Hsu, CD; Lin, MY; Lu, CC; Shen, CH, 2013) |
| " The aim of this study was to investigate the inhibitory effects of mitomycin C (MMC) combined with a novel antibody fragment (Fab) targeting latent membrane protein 1 (LMP1) on nasopharyngeal carcinoma (NPC) xenograft nude mice." | 3.78 | A novel LMP1 antibody synergizes with mitomycin C to inhibit nasopharyngeal carcinoma growth in vivo through inducing apoptosis and downregulating vascular endothelial growth factor. ( Cao, Q; Chen, RJ; Feng, ZQ; Mao, Y; Wen, J; Zhang, DW; Zhu, J, 2012) |
| "The patients included were 145 who had colorectal or appendiceal carcinomatosis resected using cytoreductive surgery prior to treatment with hyperthermic intraperitoneal chemotherapy with mitomycin C as part of a multidrug regimen." | 3.77 | Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis. ( Chang, D; Mahteme, H; Stuart, OA; Sugarbaker, PH; Van der Speeten, K, 2011) |
| "This monoinstitutional retrospective study compares the results of both treatment schedules: 315 patients with locally advanced carcinoma (UICC stage III and IV) of the oral cavity and the orohypopharynx were treated from January 1990 to March 2006 with a radiochemotherapy combination based on mitomycin C and fluorouracil (HART-CC: 203 patients, CFRT-CC: 112 patients, total dose: 70-72 Gy) with curative intent." | 3.75 | Hyperfractionated accelerated radiotherapy versus conventional fractionation both combined with chemotherapy in patients with locally advanced head and neck carcinomas: a retrospective analysis of a monoinstitutional series. ( Abu Jawad, J; Budach, V; Jahnke, K; Lehnerdt, G; Pöttgen, C; Sack, H; Stüben, G; Stuschke, M; Welz, H; Wierlemann, A; Wittig, A, 2009) |
| "The national Prostatic Cancer Project has evaluated single and combination chemotherapeutic agents for the treatment of patients with advanced prostatic cancer that has been unresponsive to hormonal therapy." | 3.75 | Chemotherapy of hormonally unresponsive prostatic carcinoma. ( deKernion, JB; Lindner, A, 1984) |
| "From January 1991 to December 2006, 18 patients with invasive carcinoma of the male urethra referred to our institution were treated with a chemoradiation therapy protocol, consisting of 2 cycles of 5-fluorouracil (1,000 mg/m(2)) on days 1 to 4 and days 29 to 32, and mitomycin-C (10 mg/m(2)) on days 1 and 29 with concurrent external beam radiation therapy (45 to 55 Gy in 25 fractions during 5 weeks) to the genitalia, perineum, and inguinal and external iliac lymph nodes." | 3.74 | Coordinated chemoradiation therapy with genital preservation for the treatment of primary invasive carcinoma of the male urethra. ( Billmeyer, B; Cohen, MS; Girshovich, L; Hanley, RS; Oberfield, RA; Shuster, T; Triaca, V; Zinman, L, 2008) |
| " Similarly, constitutive hTERT expression inhibited wild-type p53-dependent apoptosis in response to mitomycin C or 5-fluorouracil in HCT116 colon carcinoma cells carrying endogenous p53." | 3.73 | hTERT antagonizes p53-induced apoptosis independently of telomerase activity. ( Latonen, L; Rahman, R; Wiman, KG, 2005) |
| "Patients undergoing cytoreductive surgery and perioperative hyperthermic chemotherapy (mitomycin C, intraoperatively; 5-fluorouracil early post-operatively) for peritoneal carcinomatosis from colorectal cancer from 1996 to 2003 were evaluated retrospectively." | 3.73 | Treatment of peritoneal carcinomatosis from colorectal cancer by cytoreductive surgery and hyperthermic perioperative intraperitoneal chemotherapy. ( Ceranic, MS; Kecmanovic, DM; Kovacevic, PA; Pavlov, MJ; Sepetkovski, AV; Stamenkovic, AB, 2005) |
| " We examined whether D-Fraction could decrease the effective dosage of the chemotherapeutic agent, mitomycin-C (MMC), necessary to control carcinoma in mice." | 3.73 | Maitake D-Fraction enhances antitumor effects and reduces immunosuppression by mitomycin-C in tumor-bearing mice. ( Asakawa, A; Hayashi, M; Inui, A; Kodama, N; Murata, Y; Nanba, H; Sakai, N, 2005) |
| "To report the effect of regional combination chemotherapy in a cohort of patients with inoperable pancreatic carcinoma treated with or without low-dose warfarin." | 3.73 | Effects of low-dose warfarin and regional chemotherapy on survival in patients with pancreatic carcinoma. ( Löhr, M; Müller, H; Nakchbandi, IA; Nakchbandi, W; Singer, MV, 2006) |
| "Cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis is used as a palliative treatment for a variety of malignancies." | 3.72 | Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. ( Fleming, RA; Lehman, AB; Levine, EA; Loggie, BW; McQuellon, RP; Russell, GB; Shen, P, 2003) |
| "We performed a retrospective chart review of a prospective database for patients undergoing CS and IPHC with mitomycin C for peritoneal carcinomatosis from colorectal primary lesions between December 1991 and April 2002." | 3.72 | Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. ( Fleming, RA; Geisinger, KR; Hawksworth, J; Levine, EA; Loggie, BW; Lovato, J; Shen, P, 2004) |
| "Topical application of mitomycin C was effective to prevent anterior glottic synechia after transoral laser surgery for glottic carcinoma involving the anterior commissure." | 3.72 | [Mitomycin C: prevention and treatment of anterior glottic synechia]. ( Brasnu, D; de Monès, E; Hans, S; Laccourreye, O; Lagarde, F; Ménard, M, 2004) |
| " To test the absolute requirement for caspase-3, we examined mitomycin C (MMC)-induced apoptosis in the caspase-3 deficient human breast cancer cell line MCF-7." | 3.71 | Mitomycin C induces apoptosis and caspase-8 and -9 processing through a caspase-3 and Fas-independent pathway. ( Betticher, DC; Borner, MM; Pirnia, F; Schneider, E, 2002) |
| "We retrospectively reviewed 47 patients with locally advanced or bulky cervical carcinoma treated with two courses of intraarterial infusion of cisplatin, doxorubicin, mitomycin C, and 5-fluorouracil (5-FU), followed by radical hysterectomy at our hospital between 1988 and 1995." | 3.70 | Tumor response to neoadjuvant chemotherapy correlates with the expression of P-glycoprotein and PCNA but not GST-pi in the tumor cells of cervical carcinoma. ( Kataoka, N; Konishi, I; Mandai, M; Mori, T; Nagata, Y; Nanbu, K; Tsuruta, Y, 1998) |
| "To apply (HIPEC) using mitomycin in patients with peritoneal carcinomatosis." | 3.70 | [Hyperthermic intra-peritoneal chemotherapy (HIPEC) in patients with peritoneal pseudomyxoma or peritoneal metastases of colorectal carcinoma; good preliminary results from the Netherlands Cancer Institute]. ( Beijnen, JH; Boot, H; Kaag, MM; van der Vange, N; Witkamp, AJ; Zoetmulder, FA, 1999) |
| "A 71-year-old man developed an exfoliative dermatitis of the palms of the hands and soles of the feet, and a generalized itch, during treatment with intravesical instillations of mitomycin C for an undifferentiated carcinoma of the bladder." | 3.70 | Type III and type IV hypersensitivity reactions due to mitomycin C. ( Bruynzeel, DP; Kunkeler, L; Nieboer, C, 2000) |
| "Between 1982 and 1992, 139 patients with epidermoid carcinoma of the anal canal were treated by radiation and chemotherapy with 5-fluorouracil (5-Fu) and mitomycin C (MMC)." | 3.69 | [The prognostic factors following the simultaneous radiochemotherapy of anal canal carcinoma in a multicenter series of 139 patients]. ( Budach, V; Döker, R; Grabenbauer, GG; Huber, K; Hültenschmidt, B; Hutter, M; Kuhne-Velte, HJ; Panzer, M; Rühl, U; Wendt, T, 1994) |
| "In 62 human gastric carcinomas, the expression of GST pi was immunohistochemically evaluated, and sensitivity to the anticancer drugs, cisplatin (CDDP), doxorubicin (DXR) aclacinomycin A (aclarubicin), (ACR), 5-fluorouracil (5-FU), mitomycin C (MMC) and carboquone (carbazilquinon) (CQ) was examined using the in vitro succinate dehydrogenase inhibition test." | 3.69 | Expression of glutathione S-transferase-pi and sensitivity of human gastric cancer cells to cisplatin. ( Adachi, Y; Baba, H; Endo, K; Kuwano, M; Maehara, Y; Okuyama, T; Sugimachi, K, 1994) |
| "This study describes characteristics of a human bladder cancer cell line J82/MMC that is 6-fold more resistant to mitomycin C (MMC) than the parental cells." | 3.69 | Characterization of a human bladder cancer cell line selected for resistance to mitomycin C. ( Gupta, V; Singh, SV; Xu, BH, 1994) |
| "Presentation of one study on the incidence of fibrino-necrotic ulcers in patients undergoing endovesical chemoprophylaxis with mitomycin C." | 3.69 | [Fibrino-necrotic ulcers in endovesical chemoprophylaxis in superficial bladder carcinoma: our case histories]. ( Arnáiz Esteban, F; Espuela Orgaz, R; Fernández Rosáenz, J; Guinda Sevillano, C; Martínez Pérez, E; Nogueras Gimeno, MA; Pérez Arbej, JA, 1994) |
| " Adenocarcinoma patients receive mitomycin C and 5-fluorouracil; sarcoma patients receive cisplatin and doxorubicin." | 3.69 | Intraperitoneal chemotherapy for treatment and prevention of peritoneal carcinomatosis and sarcomatosis. ( Sugarbaker, PH, 1994) |
| "Twenty-nine women, ages 30-58 years, with advanced ovarian carcinoma were treated with a developmental combination chemotherapy regimen consisting of mitomycin C, etoposide, cisplatin, and carboplatin (MECCA)." | 3.69 | "MECCA": a developmental, dose-intensive, non-cross-resistant platinum-based chemotherapy for advanced ovarian cancer. ( Hoskins, PJ; Lee, N; McMurtrie, EM; Pike, JA; Swenerton, KD, 1996) |
| "Mitomycin C (MC) was reductively activated by DT-diaphorase [DTD; NAD(P)H:quinone oxidoreductase] from rat liver carcinoma cells in the presence of Micrococcus lysodeicticus DNA at pH 5." | 3.69 | Mitomycin C-DNA adducts generated by DT-diaphorase. Revised mechanism of the enzymatic reductive activation of mitomycin C. ( Cummings, J; Lipman, R; Suresh Kumar, G; Tomasz, M, 1997) |
| "The authors report the first results using intraperitoneal hyperthermic chemotherapy with mitomycin C or cisplatinum with protective hypothermia up to 32 degrees C in four cases of peritoneal carcinomatosis secondary to cancer of the ovary which was resistant to conventional treatment." | 3.68 | [Intraperitoneal chemo-hyperthermia in the treatment of peritoneal carcinomatosis of ovarian origin. Initial cases, physiopathologic data]. ( Brachet, A; Braillon, G; Carry, PY; Gilly, FN; Salle, B; Sayag, A, 1993) |
| "The intensity of lymphoid cell infiltration and distribution of lymphocyte subsets in tumors were investigated immunohistochemically on tumor tissues obtained from 11 patients with gastric carcinoma, who had been treated with mitomycin C (MMC), 12 mg/m2, i." | 3.68 | Immunohistochemical analysis of lymphocyte subsets infiltrating gastric carcinoma after mitomycin C administration. ( Adachi, M; Akiyoshi, T; Arinaga, S; Inoue, H; Karimine, N; Korenaga, D; Ueo, H, 1992) |
| "We analyzed 29 cases of eosinophilic cystitis in a group of 80 patients with lower urothelial carcinoma who had been treated with mitomycin-C." | 3.68 | [Eosinophilic cystitis as a special form of response to mitomycin C. Analysis and comments on our cases]. ( Arango Toro, O; Bielsa Galí, O; Corominas, J; Gelabert Mas, A; Lladó Carbonell, C; Vesa Llanes, J, 1991) |
| "We retrospectively examined the long-term results of adjuvant chemotherapy with mitomycin-C (MMC) in 50 patients with gastric carcinoma invading the adjacent organs." | 3.68 | Adjuvant mitomycin-C prolongs survival time of patients undergoing extensive en bloc resection of carcinoma of the stomach invading the adjacent organs. ( Baba, H; Haraguchi, M; Kakeji, Y; Korenaga, D; Maehara, Y; Orita, H; Sugimachi, K; Watanabe, A, 1990) |
| "Prognostic factors were identified in a group of 210 patients with inflammatory breast carcinoma (IBC) treated at Institut Gustave Roussy from 1976-1985 with three successive induction protocols: Group A (n = 91), 1976-1980, doxorubicin, vincristine, methotrexate (AVM); Group B (n = 79), 1980-1982, doxorubicin, vincristine, cyclophosphamide, methotrexate, 5-fluorouracil (AVCMF); Group C (n = 40), 1983-1985, AVCMF." | 3.68 | Therapeutic strategies in inflammatory breast carcinoma based on prognostic factors. ( Friedman, S; Mouriesse, H; Rouëssé, J; Sarrazin, D; Spielmann, M, 1990) |
| "Three patients with metastatic carcinoma of the ampulla of Vater received celiac artery infusion of 5-fluorouracil, adriamycin, mitomycin-C, and streptozotocin followed by intravenous administration of the same combination." | 3.67 | Combination chemotherapy for metastatic carcinoma of the ampulla of Vater--report of three cases. ( Bukowski, RM; Hermann, RE; Theodors, A, 1984) |
| "The disposition kinetics of the cancer chemotherapeutic agent mitomycin C have been studied in six male patients receiving mitomycin C in combination with cisplatin and vinblastine for non-oat cell carcinoma of the lung." | 3.67 | Pharmacokinetics of mitomycin C in non-oat cell carcinoma of the lung. ( Buice, RG; Gurley, BJ; Niell, HB; Sidhu, P, 1984) |
| "Eighty-nine patients with advanced gastric carcinoma were treated with a combination chemo-immunotherapy regimen that consisted of active immunotherapy with Vibrio cholerae neuraminidase (VCN) treated autologous tumor cells admixed with BCG and drugs including cyclophosphamide, mitomycin C (MMC) and 5-fluorouracil, followed by long term tegafur (FT) and immunomodulators." | 3.67 | Combination chemoimmunotherapy for advanced gastric carcinoma. ( Akiyoshi, T; Arinaga, S; Kawaguchi, M; Koba, F; Miyazaki, S; Tsuji, H; Wada, T, 1984) |
| " We determined the increase in antineoplastic activities of mitomycin C (MMC) and carboquone (CQ) against human tumor cells under conditions of in vitro hypoxia, with the following results." | 3.67 | Hypoxia enhances the lethality of mitomycin C and carboquone against human malignant tumor cells in vitro. ( Kusumoto, T; Maehara, Y; Sakaguchi, Y; Saku, M; Sugimachi, K, 1989) |
| "Hexamethylmelamine, mitomycin C and 5-fluorouracil infusion (HexMF) achieved a median survival of 9 months for the 45 patients with either metastatic stage III or unresectable stage II carcinoma of the pancreas." | 3.67 | Primary treatment of regional and disseminated pancreatic cancer with hexamethylmelamine, mitomycin C and 5-fluorouracil infusion. ( Bruckner, HW; Butwell, N; Gorbaty, MI; Kalman, J; McKenna, A; Spigelman, M; Storch, J, 1989) |
| "Twenty-four patients with carcinoma of the anus were treated with a combined regimen of external irradiation (50 Gy) and mitomycin C and 5-fluorouracil." | 3.67 | Primary treatment of carcinoma of the anus by combined radiotherapy and chemotherapy. ( Flokkmann, A; Fosså, SD; Guldvog, I; Haffner, J; Karlsen, KO; Tveit, KM, 1989) |
| "KW 2083, which is a new mitomycin C derivative currently under clinical investigation, was tested for its antitumor effect on the growth of human carcinoma of the lung by using an in vitro clonogenic assay system." | 3.67 | Evaluation of a new drug 7-N-(p-hydroxyphenyl)-mitomycin C [KW 2083] against carcinoma of the lung by the human tumor clonogenic assay. ( Hoshi, A; Kanzawa, F; Matsushima, Y; Miyazawa, N; Saijo, N; Shimizu, E, 1985) |
| " Patients (aged ≥18 years) with primary or recurrent biopsy-proven, low-grade upper tract urothelial cancer (measuring 5-15 mm in maximum diameter) and an Eastern Cooperative Oncology Group performance status score of less than 3 (Karnofsky Performance Status score >40) were registered to receive six instillations of once-weekly UGN-101 (mitomycin 4 mg per mL; dosed according to volume of patient's renal pelvis and calyces, maximum 60 mg per instillation) via retrograde catheter to the renal pelvis and calyces." | 2.94 | Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. ( Adibi, M; Amin, MB; Chamie, K; Coleman, J; Godoy, G; Gore, JL; Hakim, G; Hu, B; Hubosky, S; Humphreys, MR; Kaimakliotis, H; Klein, I; Kleinmann, N; Knoedler, JJ; Konorty, M; Lerner, SP; Lifshitz, D; Linehan, J; Matin, SF; O'Donnell, M; Pak, R; Pierorazio, PM; Quek, M; Raman, JD; Rivera, M; Scherr, D; Schoenberg, M; Seltzer, E; Shabsigh, A; Smith, AB; Stern, J; Strauss-Ayali, D; Verni, M; Weight, C; Weizer, A; Woods, M, 2020) |
| "Peritoneal carcinomatosis (PC) is a difficult clinical challenge in colorectal cancer (CRC) because conventional treatment modalities could not produce significant survival benefit, which highlights the acute need for new treatment strategies." | 2.79 | Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for patients with peritoneal carcinomatosis from colorectal cancer: a phase II study from a Chinese center. ( Huang, CQ; Li, Y; Liu, Y; Wu, HT; Yang, XJ; Yonemura, Y; Yu, Y, 2014) |
| "The median (range) peritoneal carcinomatosis index was 13 (3-20) requiring a median operative time of 6." | 2.78 | A phase I trial of thermal sensitization using induced oxidative stress in the context of HIPEC. ( Harrison, LE; Razavi, R; Tiesi, G; Wang, CC, 2013) |
| "The first UKCCCR Anal Cancer Trial (1996) demonstrated the benefit of chemoradiation over radiotherapy (RT) alone for treating epidermoid anal cancer, and it became the standard treatment." | 2.75 | Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). ( Glynne-Jones, R; James, R; Jitlal, M; Ledermann, J; Meadows, H; Northover, J; Sebag-Montefiore, D; Wan, S, 2010) |
| "Patients with peritoneal carcinomatosis have a uniformly poor prognosis." | 2.71 | Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. ( Case, D; Fleming, R; Geisinger, KR; Hall, J; Levine, EA; Loggie, BW; McQuellon, R; Russell, G; Shen, P, 2003) |
| "A retrospective study of 46 patients treated for peritoneal carcinomatosis from colon adenocarcinoma was performed." | 2.71 | Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from colon adenocarcinoma. ( Campana, L; Foletto, M; Lise, M; Mocellin, S; Nitti, D; Pilati, P; Rossi, CR, 2003) |
| "Despite curative resection, 50%-90% of gastric cancer patients die of disease relapse." | 2.71 | Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer. ( Czupryna, A; Kulig, J; Popiela, T; Szczepanik, AM; Zembala, M, 2004) |
| "Progression-free and freedom from metastases rates were 29." | 2.71 | Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy coo ( Bamberg, M; Baumann, M; Budach, V; Budach, W; Geismar, D; Grabenbauer, G; Herrmann, T; Hinkelbein, W; Jahnke, K; Lammert, I; Stueben, G; Stuschke, M; Wernecke, KD; Wust, P, 2005) |
| "Peritoneal carcinomatosis of colorectal cancer is probably best treated by cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC)." | 2.71 | Long-term survival of peritoneal carcinomatosis of colorectal origin. ( Boot, H; van Ruth, S; van Slooten, G; Verwaal, VJ; Witkamp, A; Zoetmulder, FA, 2005) |
| "IPHP appears to be an effective treatment for peritoneal carcinomatosis." | 2.69 | [Peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemohyperthermia]. ( Balique, JG; Porcheron, J; Rey, Y; Szafnicki, K; Talabard, JN, 2000) |
| "Of 104 patients with peritoneal carcinomatosis from colon or rectal adenocarcinoma, five patients (4." | 2.69 | Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management. ( Pestieau, SR; Sugarbaker, PH, 2000) |
| " Pharmacokinetic data from these patients showed very low plasma levels both for KW-2149, as for both known metabolites M-16 and M-18." | 2.68 | Phase I and pharmacokinetic study of KW-2149 given by 24 hours continuous infusion. ( Ardiet, C; Catimel, G; De Bruijn, E; Dirix, L; Tranchand, B; Van Oosterom, A; Verdonk, R, 1995) |
| "The drugs used in the treatment of bladder cancer are represented by the products referred to diagnosis (hexyl aminolevulinate), the intravesical instillations for the treatment of tumors not infiltrating the muscle and the infiltrating tumor chemotherapy (neo-adjuvant treatment or metastatic tumors)." | 2.49 | [Medical treatment of bladder carcinoma]. ( Bastide, C; Bay, JO; Bruyere, F; Guy, L; Karsenty, G; Mahammedi, H, 2013) |
| " Our data indicate that dosing based on body surface area is rational and reliable." | 2.42 | Pharmacokinetics of intraperitoneal mitomycin C. ( van Ruth, S; Verwaal, VJ; Zoetmulder, FA, 2003) |
| "Peritoneal carcinomatosis is a common manifestation of digestive-tract cancer and has been regarded a terminal disease with a short median survival." | 2.42 | Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. ( Gilly, FN; Glehen, O; Mohamed, F, 2004) |
| "Mitomycin-C (MMC) was used in 20% and oxaliplatin in 10%." | 1.56 | Toxicity profile of chemotherapy agents used in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies. ( Ashwin, KR; Kumar C, R; Rauthan, A; Somashekhar, SP; Yethadka, R; Zaveri, S, 2020) |
| "Colorectal peritoneal carcinomatosis (PC) is commonly treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)." | 1.48 | Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC. ( Aalbers, AGJ; Boot, H; Huitema, ADR; Kok, NFM; van Eden, WJ; Woensdregt, K, 2018) |
| "Weight loss was common after HIPEC as 38 of 41 patients demonstrated weight loss." | 1.43 | Feeding tube placement during cytoreductive surgery and heated intraperitoneal chemotherapy does not improve postoperative nutrition and is associated with longer length of stay and higher readmission rates. ( Beaty, KA; Dineen, SP; Fournier, KF; Mansfield, PF; Rafeeq, S; Robinson, KA; Roland, CL; Royal, RE, 2016) |
| "45 patients with anal cancer who underwent pre-treatment FDG-PET/CT were included." | 1.43 | Metabolic tumour volume of anal carcinoma on (18)FDG PET/CT before combined radiochemotherapy is the only independant determinant of recurrence free survival. ( Behrendt, FF; Eble, MJ; Heinzel, A; Mohammadkhani Shali, S; Mottaghy, FM; Schmitt, V; Verburg, FA; Winz, OH, 2016) |
| "In Taiwan, colorectal cancer with peritoneal carcinomatosis is considered a terminal condition." | 1.43 | Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with peritoneal metastasis. ( Chen, CH; Hsieh, MC; Lin, EK; Lu, YJ; Wu, SY, 2016) |
| "To treat carcinomatosis, we use cytoreductive surgery (CS) with hyperthermic intraperitoneal chemotherapy (HIPEC)." | 1.40 | Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. ( Levine, EA; Loggie, BL; Russell, GB; Shen, P; Stewart, JH; Votanopoulos, KI, 2014) |
| "Mitomycin C (88." | 1.40 | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution. ( Hiotis, S; Jibara, G; Labow, DM; Romanoff, A; Sarpel, U; Shrager, B; Tabrizian, P; Yang, MJ, 2014) |
| "Treatment of peritoneal carcinomatosis (PC) of colorectal cancer (CRC) origin is relatively ineffective and associated with morbidity." | 1.40 | Feasibility of adjuvant laparoscopic hyperthermic intraperitoneal chemotherapy in a short stay setting in patients with colorectal cancer at high risk of peritoneal carcinomatosis. ( Bemelman, WA; Buskens, CJ; Crezee, J; Gardenbroek, TJ; Punt, CJ; Sloothaak, DA; Tanis, PJ, 2014) |
| "Among the CRC and appendiceal cancer group the median overall survival was 20." | 1.40 | [Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal and appendiceal origin]. ( Aderka, D; Berger, Y; Brenner, B; Golan, T; Gutman, M; Lebedyev, A; Levi, Y; Natur, M; Nevler, A; Purim, O; Zbar, AP, 2014) |
| "Patients with PC from colorectal or appendiceal cancer, pseudomyxoma peritonei or malignant peritoneal mesothelioma referred to the single national HIPEC centre were prospectively registered from June 2006 to July 2012." | 1.39 | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: the Danish experience. ( Hagemann-Madsen, R; Iversen, LH; Laurberg, S; Rasmussen, PC, 2013) |
| " Diffuse colorectal carcinomatosis was generated in mice prior to intraperitoneal lavage with mitomycin C (MMC) at clinically comparable dosing for variable lengths of time." | 1.39 | The benefit of intraperitoneal chemotherapy for the treatment of colorectal carcinomatosis. ( Attwood, K; Camoriano, M; Francescutti, V; Haslinger, M; Kane, JM; Kim, M; Rivera, L; Seshadri, M; Skitzki, JJ, 2013) |
| "Pseudomyxoma peritonei and peritoneal carcinomatosis derived from appendiceal epithelial tumors are controversial entities from classification to treatment." | 1.39 | Controversy and consensus on the management of patients with pseudomyxoma peritonei. ( Faris, JE; Ryan, DP, 2013) |
| "Choanal stenosis is a well recognized late complication of radiotherapy for nasopharyngeal carcinoma." | 1.39 | Velopharyngeal and choanal stenosis after radiotherapy for nasopharyngeal carcinoma. ( Chong, AW; Hussein, J; Narayanan, P; Omar, R; Tan, TS, 2013) |
| "The vincristine-resistant human gastric cancer cell line SGC7901/VCR and its parental cell line SGC7901 were treated with ROS, MMC (negative control), cyclosporine A+MMC (positive control) or ROS+MMC." | 1.38 | Rosiglitazone reverses mitomycin C resistance in human gastric cancer cells. ( Hu, JF; Li, GQ; Su, Q; Xiao, X; Zhang, L, 2012) |
| "We report on a 45-year-old breast cancer patient with disseminated hepatic metastases." | 1.36 | Successful remission of extensive liver metastases in a breast cancer patient with acute liver failure using a combined chemotherapy regimen with mitomycin, folinate, and 5-fluorouracil (Mi/Fo/FU). ( Eichbaum, MH; Hauser, N; Hohl, MK; Sohn, C; Stoiber, B; Stoiber, N, 2010) |
| "Colorectal cancer with peritoneal carcinomatosis is usually considered incurable." | 1.32 | Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. ( Cotte, E; Gilly, FN; Glehen, O; Sayag-Beaujard, AC; Schreiber, V; Vignal, J, 2004) |
| "Mitomycin C was administered as a perfusate at 10 mg/l." | 1.32 | Treatment of peritoneal carcinomatosis in patients with digestive cancers with combination of intraperitoneal hyperthermia and mitomycin C. ( Banssillon, V; Bienvenu, J; Francois, Y; Garbit, F; Gilly, FN; Glehen, O; Grandclément, E; Panteix, G; Sadeghi-Looyeh, B; Sayag-Beaujard, AC; Vignal, J, 2004) |
| "The prognosis for intraabdominal carcinomatosis is poor with conventional treatments and modalities." | 1.31 | Intraoperative modality of treatment for peritoneal carcinomatosis: use of hyperthermic interperitoneal chemoperfusion. ( Chase, VA; Hunley, EK; Kuhn, JA; Loggie, BW; McCarty, TM; Sutton, SW; Yancey, LW, 2002) |
| " Thirty-one patients with superficial oesophageal or gastric cardiac carcinomas, who refused or were unsuitable for surgery, received endoscopic Nd:YAG laser therapy combined with local injection of chemotherapeutic drugs 5-fluorouracil and mitomycin." | 1.31 | Endoscopic Nd:YAG laser therapy combined with local chemotherapy of superficial carcinomas of the oesophagus and gastric cardia. ( Huang, T; Jia, J; Wang, Y; Zhou, C, 2001) |
| "IHCP combined with aggressive surgery was performed in 48 gastric carcinoma patients with peritoneal carcinomatosis; 18 gastric carcinoma patients with peritoneal carcinomatosis serving as controls were treated with surgery alone." | 1.30 | Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery. ( Fujimoto, S; Isawa, E; Kobayashi, K; Mutou, T; Ohkubo, H; Sumida, M; Takahashi, M; Toyosawa, T, 1997) |
| "Eleven patients with T4 breast cancer received induction intraarterial chemotherapy (IACT) as the first step in multidisciplinary therapy." | 1.30 | Induction intraarterial chemotherapy for T4 breast cancer through an implantable port-catheter system. ( Chang, HT; Mok, KT; Tzeng, WS, 1997) |
| "We report 42 cases of gastric cancer with peritoneal carcinosis treated with intraperitoneal chemohyperthermia." | 1.30 | [Intraperitoneal chemo-hyperthermia with mitomycin C in cancer of the stomach with peritoneal carcinosis]. ( Bienvenu, J; François, Y; Garbit, F; Gilly, FN; Glehen, O; Grandclément, E; Peyrat, PP; Sadeghi-Looyeh, B; Sayag-Beaujard, AC; Vignal, J, 1997) |
| "A group of 298 patients with epithelial ovarian cancer were treated with combination chemotherapy between July 1979 and January 1986 at the Tokai Ovarian Tumor Study Group." | 1.29 | Long-term follow-up of patients with epithelial carcinoma of the ovary. ( Arii, Y; Hattori, S; Kawai, M; Kikkawa, F; Ohta, M; Tomoda, Y, 1994) |
| "Mitomycin C (10 mg/m2) was administered as a bolus injection on day 2." | 1.28 | Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma. ( Coia, LR; Engstrom, PF; Hanks, GE; Paul, AR; Stafford, PM, 1991) |
| "Nineteen patients with resectable pancreatic cancer have been treated by a multidisciplinary approach at the National Cancer Center Hospital." | 1.28 | Evidence of effective multidisciplinary treatment for resectable pancreatic cancer from the viewpoint of the CA19-9 level. ( Egawa, S; Kinoshita, T; Kosuge, T; Ozaki, H; Shimada, K; Yamamoto, J, 1991) |
| "Twenty-eight patients with inflammatory breast cancer were treated with combined modality therapy consisting of (1) intraarterial infusion chemotherapy (IA chemotherapy) through the internal thoracic artery and subclavian artery, (2) surgical ablation, (3) extended radical mastectomy, and (4) adjuvant chemotherapy in that order." | 1.27 | Management of inflammatory carcinoma of the breast with combined modality therapy including intraarterial infusion chemotherapy as an induction therapy. Long-term follow-up results of 28 patients. ( Koyama, H; Miyauchi, K; Nishizawa, Y; Noguchi, S; Terasawa, T, 1988) |
| "Persistent or recurrent peritoneal carcinomatosis (PC) documented at second-look surgery has proved relatively refractory to second-line therapy." | 1.27 | Intraperitoneal mitomycin C in the treatment of peritoneal carcinomatosis following second-look surgery. ( Alberts, DS; Graham, V; Monk, BJ; Surwit, EA, 1988) |
| " This three-drug combination appears to be an active regimen in the treatment of non-small-cell bronchogenic carcinoma; however, altered dosage schedules should be examined in order to decrease drug-related toxicity." | 1.27 | Combination chemotherapy with mitomycin-C, cisplatin, and vinblastine in the treatment of non-small-cell lung cancer. ( Griffin, JP; Niell, HB, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 45 (21.74) | 18.7374 |
| 1990's | 55 (26.57) | 18.2507 |
| 2000's | 54 (26.09) | 29.6817 |
| 2010's | 44 (21.26) | 24.3611 |
| 2020's | 9 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Kakadiya, R | 1 |
| Dong, H | 1 |
| Lee, PC | 1 |
| Kapuriya, N | 1 |
| Zhang, X | 1 |
| Chou, TC | 1 |
| Lee, TC | 1 |
| Kapuriya, K | 1 |
| Shah, A | 1 |
| Su, TL | 1 |
| Matin, SF | 2 |
| Pierorazio, PM | 2 |
| Kleinmann, N | 2 |
| Gore, JL | 2 |
| Shabsigh, A | 2 |
| Hu, B | 2 |
| Chamie, K | 2 |
| Godoy, G | 2 |
| Hubosky, SG | 1 |
| Rivera, M | 2 |
| O'Donnell, M | 2 |
| Quek, M | 2 |
| Raman, JD | 2 |
| Knoedler, JJ | 2 |
| Scherr, D | 2 |
| Weight, C | 2 |
| Weizer, A | 2 |
| Woods, M | 2 |
| Kaimakliotis, H | 2 |
| Smith, AB | 2 |
| Linehan, J | 2 |
| Coleman, J | 2 |
| Humphreys, MR | 2 |
| Pak, R | 2 |
| Lifshitz, D | 2 |
| Verni, M | 2 |
| Klein, I | 2 |
| Konorty, M | 2 |
| Strauss-Ayali, D | 2 |
| Hakim, G | 2 |
| Seltzer, E | 2 |
| Schoenberg, M | 2 |
| Lerner, SP | 2 |
| Gallo, RA | 1 |
| Lang, SH | 1 |
| Gomez, A | 1 |
| Sabater, AL | 1 |
| Tse, DT | 1 |
| Pelaez, D | 1 |
| Rong, AJ | 1 |
| Somashekhar, SP | 1 |
| Yethadka, R | 1 |
| Kumar C, R | 1 |
| Ashwin, KR | 1 |
| Zaveri, S | 1 |
| Rauthan, A | 1 |
| Hentzen, JEKR | 1 |
| van der Plas, WY | 1 |
| Kuipers, H | 1 |
| Ramcharan, S | 1 |
| Been, LB | 1 |
| Hoogwater, FJH | 1 |
| van Ginkel, RJ | 1 |
| van Dam, GM | 1 |
| Hemmer, PHJ | 1 |
| Kruijff, S | 1 |
| Hulshof, EC | 1 |
| Lurvink, RJ | 1 |
| Caserta, N | 1 |
| de Hingh, IHJT | 1 |
| van Wezel, T | 1 |
| Böhringer, S | 1 |
| Swen, JJ | 1 |
| Gelderblom, H | 1 |
| Guchelaar, HJ | 1 |
| Deenen, MJ | 1 |
| Hubosky, S | 1 |
| Stern, J | 1 |
| Adibi, M | 1 |
| Amin, MB | 1 |
| García-Olmo, D | 1 |
| Villarejo Campos, P | 1 |
| Barambio, J | 1 |
| Gomez-Heras, SG | 1 |
| Vega-Clemente, L | 1 |
| Olmedillas-Lopez, S | 1 |
| Guadalajara, H | 1 |
| Garcia-Arranz, M | 1 |
| Loaec, C | 1 |
| Guérin-Charbonnel, C | 1 |
| Vignaud, T | 1 |
| Paineau, J | 1 |
| Thibaudeau, E | 1 |
| Dumont, F | 1 |
| Gierth, M | 1 |
| Breyer, J | 1 |
| Zeman, F | 1 |
| Fritsche, HM | 1 |
| Cordes, J | 1 |
| Karl, A | 1 |
| Zaak, D | 1 |
| Stenzl, A | 1 |
| von Schmeling, IK | 1 |
| Sommerhuber, A | 1 |
| Zierer, T | 1 |
| Burger, M | 1 |
| Mayr, R | 1 |
| Gayarre, J | 1 |
| Martín-Gimeno, P | 1 |
| Osorio, A | 1 |
| Paumard, B | 1 |
| Barroso, A | 1 |
| Fernández, V | 1 |
| de la Hoya, M | 1 |
| Rojo, A | 1 |
| Caldés, T | 1 |
| Palacios, J | 1 |
| Urioste, M | 1 |
| Benítez, J | 2 |
| García, MJ | 1 |
| Morales-Soriano, R | 1 |
| Esteve-Pérez, N | 1 |
| Segura-Sampedro, JJ | 1 |
| Cascales-Campos, P | 1 |
| Barrios, P | 1 |
| van Eden, WJ | 1 |
| Kok, NFM | 1 |
| Woensdregt, K | 1 |
| Huitema, ADR | 1 |
| Boot, H | 3 |
| Aalbers, AGJ | 1 |
| Kozman, MA | 1 |
| Fisher, OM | 1 |
| Rebolledo, BJ | 1 |
| Parikh, R | 1 |
| Valle, SJ | 1 |
| Arrowaili, A | 1 |
| Alzahrani, N | 1 |
| Liauw, W | 1 |
| Morris, DL | 1 |
| Giuliani, A | 1 |
| Romanzi, F | 1 |
| Di Sibio, A | 1 |
| Calvisi, G | 1 |
| Lombardi, L | 1 |
| Marchese, M | 1 |
| Di Staso, M | 1 |
| Schietroma, M | 1 |
| Carlei, F | 1 |
| Romano, L | 1 |
| Lu, CC | 1 |
| Lin, MY | 1 |
| Chen, SY | 1 |
| Shen, CH | 1 |
| Chen, LG | 1 |
| Hsieh, HY | 1 |
| Chan, MW | 1 |
| Hsu, CD | 1 |
| Iversen, LH | 1 |
| Rasmussen, PC | 1 |
| Hagemann-Madsen, R | 1 |
| Laurberg, S | 1 |
| Yip, D | 1 |
| Cho, CH | 1 |
| Kepenekian, V | 1 |
| Aloy, MT | 1 |
| Magné, N | 1 |
| Passot, G | 2 |
| Armandy, E | 1 |
| Decullier, E | 1 |
| Sayag-Beaujard, A | 1 |
| Gilly, FN | 9 |
| Glehen, O | 8 |
| Rodriguez-Lafrasse, C | 1 |
| Francescutti, V | 1 |
| Rivera, L | 1 |
| Seshadri, M | 1 |
| Kim, M | 1 |
| Haslinger, M | 1 |
| Camoriano, M | 1 |
| Attwood, K | 1 |
| Kane, JM | 1 |
| Skitzki, JJ | 1 |
| Faris, JE | 1 |
| Ryan, DP | 1 |
| Sardi, A | 1 |
| Jimenez, WA | 1 |
| Nieroda, C | 1 |
| Sittig, M | 1 |
| Macdonald, R | 1 |
| Gushchin, V | 1 |
| Kostková, H | 1 |
| Etrych, T | 1 |
| Ríhová, B | 1 |
| Kostka, L | 1 |
| Starovoytová, L | 1 |
| Kovář, M | 1 |
| Ulbrich, K | 1 |
| Guy, L | 1 |
| Mahammedi, H | 1 |
| Bastide, C | 1 |
| Bruyere, F | 1 |
| Karsenty, G | 1 |
| Bay, JO | 1 |
| Bakrin, N | 1 |
| Roux, AS | 1 |
| Vaudoyer, D | 1 |
| Cotte, E | 3 |
| Levine, EA | 4 |
| Stewart, JH | 1 |
| Shen, P | 4 |
| Russell, GB | 3 |
| Loggie, BL | 1 |
| Votanopoulos, KI | 1 |
| Tabrizian, P | 1 |
| Shrager, B | 1 |
| Jibara, G | 1 |
| Yang, MJ | 1 |
| Romanoff, A | 1 |
| Hiotis, S | 1 |
| Sarpel, U | 1 |
| Labow, DM | 1 |
| Botros, L | 1 |
| Van Nieuw Amerongen, GP | 1 |
| Vonk Noordegraaf, A | 1 |
| Bogaard, HJ | 1 |
| Teo, MC | 1 |
| Ching Tan, GH | 1 |
| Lim, C | 1 |
| Chia, CS | 1 |
| Tham, CK | 1 |
| Soo, KC | 1 |
| Sloothaak, DA | 1 |
| Gardenbroek, TJ | 1 |
| Crezee, J | 1 |
| Bemelman, WA | 1 |
| Punt, CJ | 1 |
| Buskens, CJ | 1 |
| Tanis, PJ | 1 |
| Berger, Y | 1 |
| Zbar, AP | 1 |
| Lebedyev, A | 1 |
| Levi, Y | 1 |
| Nevler, A | 1 |
| Aderka, D | 1 |
| Golan, T | 1 |
| Purim, O | 1 |
| Brenner, B | 1 |
| Natur, M | 1 |
| Gutman, M | 1 |
| Huang, CQ | 1 |
| Yang, XJ | 1 |
| Yu, Y | 1 |
| Wu, HT | 1 |
| Liu, Y | 1 |
| Yonemura, Y | 1 |
| Li, Y | 1 |
| Huang, J | 1 |
| Li, Q | 1 |
| Zheng, Y | 1 |
| Shen, J | 1 |
| Li, B | 1 |
| Zou, R | 1 |
| Wang, J | 1 |
| Yuan, Y | 1 |
| Delhorme, JB | 1 |
| Triki, E | 1 |
| Romain, B | 1 |
| Meyer, N | 1 |
| Rohr, S | 1 |
| Brigand, C | 1 |
| Dineen, SP | 1 |
| Robinson, KA | 1 |
| Roland, CL | 1 |
| Beaty, KA | 1 |
| Rafeeq, S | 1 |
| Mansfield, PF | 1 |
| Royal, RE | 1 |
| Fournier, KF | 1 |
| Mohammadkhani Shali, S | 1 |
| Schmitt, V | 1 |
| Behrendt, FF | 1 |
| Winz, OH | 1 |
| Heinzel, A | 1 |
| Mottaghy, FM | 1 |
| Eble, MJ | 1 |
| Verburg, FA | 1 |
| Lin, EK | 1 |
| Hsieh, MC | 1 |
| Chen, CH | 1 |
| Lu, YJ | 1 |
| Wu, SY | 1 |
| Welz, H | 1 |
| Pöttgen, C | 1 |
| Abu Jawad, J | 1 |
| Wierlemann, A | 1 |
| Wittig, A | 1 |
| Stüben, G | 2 |
| Budach, V | 4 |
| Lehnerdt, G | 1 |
| Jahnke, K | 3 |
| Sack, H | 2 |
| Stuschke, M | 3 |
| Vardouli, L | 1 |
| Lindqvist, C | 1 |
| Vlahou, K | 1 |
| Loskog, AS | 1 |
| Eliopoulos, AG | 1 |
| Gammon, DC | 1 |
| Dutton, T | 1 |
| Piperdi, B | 1 |
| Zybert, J | 1 |
| Wolfe, SH | 1 |
| Nguyen, E | 1 |
| Sbat, D | 1 |
| Pillarisetty, VG | 1 |
| Sullivan, M | 1 |
| Whalen, GF | 1 |
| Simon, L | 1 |
| Halilou, MC | 1 |
| Gladieff, L | 1 |
| Gadiou, M | 1 |
| Herin, F | 1 |
| Hennebelle, I | 1 |
| Chatelut, E | 1 |
| Ferron, G | 1 |
| Northover, J | 1 |
| Glynne-Jones, R | 1 |
| Sebag-Montefiore, D | 1 |
| James, R | 1 |
| Meadows, H | 1 |
| Wan, S | 1 |
| Jitlal, M | 1 |
| Ledermann, J | 1 |
| Van der Speeten, K | 1 |
| Stuart, OA | 1 |
| Chang, D | 1 |
| Mahteme, H | 1 |
| Sugarbaker, PH | 5 |
| Stoiber, N | 1 |
| Hauser, N | 1 |
| Stoiber, B | 1 |
| Hohl, MK | 1 |
| Sohn, C | 1 |
| Eichbaum, MH | 1 |
| O'Brien, T | 1 |
| Ray, E | 1 |
| Singh, R | 1 |
| Coker, B | 1 |
| Beard, R | 1 |
| Boorjian, SA | 1 |
| Grossman, HB | 1 |
| Di Stasi, SM | 2 |
| Valenti, M | 1 |
| Verri, C | 1 |
| Liberati, E | 1 |
| Giurioli, A | 1 |
| Leprini, G | 1 |
| Masedu, F | 1 |
| Ricci, AR | 1 |
| Micali, F | 1 |
| Vespasiani, G | 1 |
| Klaver, YL | 1 |
| Hendriks, T | 1 |
| Lomme, RM | 1 |
| Rutten, HJ | 1 |
| Bleichrodt, RP | 1 |
| de Hingh, IH | 1 |
| Zhuchenko, AP | 2 |
| Kalganov, ID | 2 |
| Filon, AF | 2 |
| Zhang, L | 1 |
| Hu, JF | 1 |
| Li, GQ | 1 |
| Xiao, X | 1 |
| Su, Q | 1 |
| Ho, CC | 1 |
| Chen, R | 1 |
| Zhang, D | 1 |
| Mao, Y | 2 |
| Zhu, J | 2 |
| Ming, H | 1 |
| Wen, J | 2 |
| Ma, J | 1 |
| Cao, Q | 2 |
| Lin, H | 1 |
| Tang, Q | 1 |
| Liang, J | 1 |
| Feng, Z | 1 |
| Goel, A | 1 |
| Paul, S | 1 |
| Zhang, DW | 1 |
| Chen, RJ | 1 |
| Feng, ZQ | 1 |
| Machida, H | 1 |
| Tominaga, K | 1 |
| Minamino, H | 1 |
| Sugimori, S | 1 |
| Okazaki, H | 1 |
| Yamagami, H | 1 |
| Tanigawa, T | 1 |
| Watanabe, K | 1 |
| Watanabe, T | 1 |
| Fujiwara, Y | 1 |
| Arakawa, T | 1 |
| Hussein, J | 1 |
| Tan, TS | 1 |
| Chong, AW | 1 |
| Narayanan, P | 1 |
| Omar, R | 1 |
| Harrison, LE | 1 |
| Tiesi, G | 1 |
| Razavi, R | 1 |
| Wang, CC | 1 |
| Pirnia, F | 1 |
| Schneider, E | 1 |
| Betticher, DC | 1 |
| Borner, MM | 1 |
| Sutton, SW | 1 |
| Yancey, LW | 1 |
| Chase, VA | 1 |
| Hunley, EK | 1 |
| McCarty, TM | 1 |
| Kuhn, JA | 1 |
| Loggie, BW | 5 |
| Hall, J | 1 |
| Case, D | 1 |
| Russell, G | 1 |
| Fleming, R | 1 |
| McQuellon, R | 1 |
| Geisinger, KR | 2 |
| McQuellon, RP | 2 |
| Lehman, AB | 2 |
| Fleming, RA | 3 |
| Pilati, P | 1 |
| Mocellin, S | 1 |
| Rossi, CR | 1 |
| Foletto, M | 1 |
| Campana, L | 1 |
| Nitti, D | 1 |
| Lise, M | 1 |
| Tanaka, H | 1 |
| Umekawa, T | 1 |
| Nagao, K | 1 |
| Ishihara, A | 1 |
| Toyoda, N | 1 |
| KERSTEN, H | 1 |
| THEMANN, H | 1 |
| HATA, T | 1 |
| HOSSENLOPP, C | 2 |
| TAKITA, H | 1 |
| SAKAI, S | 2 |
| SAITO, G | 1 |
| SUGAYAMA, J | 1 |
| KAMASUKA, T | 1 |
| TAKADA, S | 1 |
| TAKANO, T | 1 |
| STRAUB, PW | 1 |
| NELSON, JH | 1 |
| MARIK, LR | 1 |
| BURCHENAL, JH | 1 |
| KONTANI, H | 1 |
| van Ruth, S | 2 |
| Verwaal, VJ | 2 |
| Zoetmulder, FA | 3 |
| Schreiber, V | 2 |
| Sayag-Beaujard, AC | 4 |
| Osinsky, D | 1 |
| Freyer, G | 1 |
| François, Y | 4 |
| Vignal, J | 5 |
| Hawksworth, J | 1 |
| Lovato, J | 1 |
| Chung, NC | 1 |
| Liu, YC | 1 |
| Ye, XD | 1 |
| Wang, YM | 1 |
| Kuo, MC | 1 |
| Liu, K | 1 |
| Giroux, MF | 1 |
| Baum, RA | 1 |
| Soulen, MC | 1 |
| Mohamed, F | 1 |
| Huang, X | 1 |
| Cai, SM | 1 |
| Tang, J | 1 |
| Li, ZT | 1 |
| Zang, RY | 1 |
| de Monès, E | 1 |
| Lagarde, F | 1 |
| Hans, S | 1 |
| Ménard, M | 1 |
| Laccourreye, O | 1 |
| Brasnu, D | 1 |
| Sadeghi-Looyeh, B | 2 |
| Bienvenu, J | 3 |
| Panteix, G | 2 |
| Garbit, F | 3 |
| Grandclément, E | 3 |
| Banssillon, V | 1 |
| Rahman, R | 1 |
| Latonen, L | 1 |
| Wiman, KG | 1 |
| Popiela, T | 2 |
| Kulig, J | 2 |
| Czupryna, A | 1 |
| Szczepanik, AM | 1 |
| Zembala, M | 1 |
| Kecmanovic, DM | 1 |
| Pavlov, MJ | 1 |
| Ceranic, MS | 1 |
| Sepetkovski, AV | 1 |
| Kovacevic, PA | 1 |
| Stamenkovic, AB | 1 |
| Budach, W | 1 |
| Baumann, M | 1 |
| Geismar, D | 1 |
| Grabenbauer, G | 1 |
| Lammert, I | 1 |
| Stueben, G | 1 |
| Herrmann, T | 1 |
| Bamberg, M | 1 |
| Wust, P | 1 |
| Hinkelbein, W | 1 |
| Wernecke, KD | 1 |
| Budihna, M | 1 |
| Soba, E | 1 |
| Smid, L | 1 |
| Zakotnik, B | 1 |
| Strojan, P | 1 |
| Cemazar, M | 1 |
| Fajdiga, I | 1 |
| Zargi, M | 1 |
| Zupevc, A | 1 |
| Lesnicar, H | 1 |
| Witkamp, A | 1 |
| van Slooten, G | 1 |
| Kodama, N | 1 |
| Murata, Y | 1 |
| Asakawa, A | 1 |
| Inui, A | 1 |
| Hayashi, M | 1 |
| Sakai, N | 2 |
| Nanba, H | 2 |
| Giannantoni, A | 1 |
| Stephen, RL | 1 |
| Storti, L | 1 |
| Attisani, F | 1 |
| Sansalone, S | 1 |
| Virgili, G | 1 |
| Nakchbandi, W | 1 |
| Müller, H | 1 |
| Singer, MV | 1 |
| Löhr, M | 1 |
| Nakchbandi, IA | 1 |
| Crehange, G | 1 |
| Bosset, M | 1 |
| Lorchel, F | 1 |
| Dumas, JL | 1 |
| Buffet-Miny, J | 1 |
| Puyraveau, M | 1 |
| Mercier, M | 1 |
| Bosset, JF | 1 |
| Pérez, J | 1 |
| Rodríguez, MJ | 1 |
| Campaña, O | 1 |
| Veiras, S | 1 |
| Lorenzo, D | 1 |
| Lamas, M | 1 |
| Alvarez, J | 1 |
| Seminara, P | 1 |
| Pastore, C | 1 |
| Iascone, C | 1 |
| Cicconetti, F | 1 |
| Nigita, G | 1 |
| Ielapi, T | 1 |
| Franchi, F | 1 |
| Bijelic, L | 1 |
| Yan, TD | 1 |
| Cho, YH | 1 |
| Lee, SH | 1 |
| Kim, DW | 1 |
| Wu, HG | 1 |
| Hah, JH | 1 |
| Rhee, CS | 1 |
| Sung, MW | 1 |
| Kim, KH | 1 |
| Heo, DS | 1 |
| Cohen, MS | 1 |
| Triaca, V | 1 |
| Billmeyer, B | 1 |
| Hanley, RS | 1 |
| Girshovich, L | 1 |
| Shuster, T | 1 |
| Oberfield, RA | 1 |
| Zinman, L | 1 |
| Scaringi, S | 1 |
| Kianmanesh, R | 1 |
| Sabate, JM | 1 |
| Facchiano, E | 1 |
| Jouet, P | 1 |
| Coffin, B | 1 |
| Parmentier, G | 1 |
| Hay, JM | 1 |
| Flamant, Y | 1 |
| Msika, S | 1 |
| Shimada, F | 1 |
| Bukowski, RM | 1 |
| Hermann, RE | 1 |
| Theodors, A | 1 |
| deKernion, JB | 1 |
| Lindner, A | 1 |
| Kano, T | 1 |
| Kumashiro, R | 1 |
| Masuda, H | 1 |
| Tamada, R | 1 |
| Inokuchi, K | 1 |
| Buice, RG | 1 |
| Niell, HB | 2 |
| Sidhu, P | 1 |
| Gurley, BJ | 1 |
| Fujimoto, S | 2 |
| Endoh, F | 1 |
| Miyazaki, M | 1 |
| Shreestha, RD | 1 |
| Okui, K | 1 |
| Morimoto, Y | 1 |
| Akiyoshi, T | 4 |
| Kawaguchi, M | 1 |
| Arinaga, S | 4 |
| Miyazaki, S | 1 |
| Koba, F | 1 |
| Wada, T | 1 |
| Tsuji, H | 1 |
| Imai, R | 1 |
| Morimoto, M | 1 |
| Marumo, H | 1 |
| Kobayashi, T | 1 |
| Tsuruo, T | 1 |
| Inaba, M | 1 |
| Tsukagoshi, S | 1 |
| Sakurai, Y | 1 |
| Yanai, S | 1 |
| Okada, H | 1 |
| Saito, K | 1 |
| Kuge, Y | 1 |
| Misaki, M | 1 |
| Ogawa, Y | 1 |
| Toguchi, H | 1 |
| Inoue, H | 3 |
| Adachi, M | 2 |
| Asoh, T | 1 |
| Ueo, H | 3 |
| Schwaibold, H | 1 |
| Klingenberger, HJ | 1 |
| Huland, H | 2 |
| Kawai, M | 1 |
| Kikkawa, F | 1 |
| Hattori, S | 1 |
| Ohta, M | 1 |
| Arii, Y | 1 |
| Tomoda, Y | 1 |
| Cocconi, G | 1 |
| Bella, M | 1 |
| Zironi, S | 1 |
| Algeri, R | 1 |
| Di Costanzo, F | 1 |
| De Lisi, V | 1 |
| Luppi, G | 1 |
| Mazzocchi, B | 1 |
| Rodinò, C | 1 |
| Soldani, M | 1 |
| Grabenbauer, GG | 1 |
| Panzer, M | 1 |
| Hültenschmidt, B | 1 |
| Döker, R | 1 |
| Huber, K | 1 |
| Kuhne-Velte, HJ | 1 |
| Hutter, M | 1 |
| Rühl, U | 1 |
| Wendt, T | 1 |
| Okuyama, T | 1 |
| Maehara, Y | 3 |
| Endo, K | 1 |
| Baba, H | 3 |
| Adachi, Y | 1 |
| Kuwano, M | 1 |
| Sugimachi, K | 4 |
| Xu, BH | 1 |
| Gupta, V | 1 |
| Singh, SV | 1 |
| Guinda Sevillano, C | 1 |
| Arnáiz Esteban, F | 1 |
| Fernández Rosáenz, J | 1 |
| Pérez Arbej, JA | 1 |
| Martínez Pérez, E | 1 |
| Nogueras Gimeno, MA | 1 |
| Espuela Orgaz, R | 1 |
| Philpott, NJ | 1 |
| Bevan, DH | 1 |
| Gordon-Smith, EC | 1 |
| Agostara, B | 1 |
| Gebbia, V | 1 |
| Testa, A | 1 |
| Cusimano, MP | 1 |
| Gebbia, N | 1 |
| Callari, AM | 1 |
| Salle, B | 1 |
| Carry, PY | 1 |
| Sayag, A | 1 |
| Brachet, A | 1 |
| Braillon, G | 1 |
| Taal, BG | 1 |
| Audisio, RA | 1 |
| Bleiberg, H | 1 |
| Blijham, GH | 1 |
| Neijt, JP | 1 |
| Veenhof, CH | 1 |
| Duez, N | 1 |
| Sahmoud, T | 1 |
| Denehy, TR | 1 |
| Eastman, R | 1 |
| SanFilippo, L | 1 |
| Gregori, CA | 1 |
| Breen, JL | 1 |
| Dirix, L | 1 |
| Catimel, G | 1 |
| Verdonk, R | 1 |
| De Bruijn, E | 1 |
| Tranchand, B | 1 |
| Ardiet, C | 1 |
| Van Oosterom, A | 1 |
| Landoni, F | 1 |
| Maneo, A | 1 |
| Zanetta, G | 1 |
| Colombo, A | 1 |
| Nava, S | 1 |
| Placa, F | 1 |
| Tancini, G | 1 |
| Mangioni, C | 1 |
| Plasswilm, L | 1 |
| Seegenschmiedt, MH | 1 |
| Ganssauge, F | 1 |
| Sauer, R | 1 |
| Cakmakli, S | 1 |
| Ersöz, S | 1 |
| Karaayvaz, M | 1 |
| Arat, AR | 1 |
| Tsavaris, NB | 1 |
| Tentas, K | 1 |
| Kosmidis, P | 1 |
| Mylonakis, N | 1 |
| Sakelaropoulos, N | 1 |
| Kosmas, C | 1 |
| Lisaios, B | 1 |
| Soumilas, A | 1 |
| Mandrekois, D | 1 |
| Tsetis, A | 1 |
| Klonaris, C | 1 |
| Chauveinc, L | 1 |
| Giralt, EG | 1 |
| Hoskins, PJ | 1 |
| Swenerton, KD | 1 |
| Pike, JA | 1 |
| McMurtrie, EM | 1 |
| Lee, N | 1 |
| Takahashi, M | 2 |
| Mutou, T | 1 |
| Kobayashi, K | 1 |
| Toyosawa, T | 1 |
| Isawa, E | 1 |
| Sumida, M | 1 |
| Ohkubo, H | 1 |
| Shimizu, Y | 1 |
| Sanz-Altamira, PM | 1 |
| Spence, LD | 1 |
| Huberman, MS | 1 |
| Posner, MR | 1 |
| Steele, G | 1 |
| Perry, LJ | 1 |
| Stuart, KE | 1 |
| Gomez Torrijos, E | 1 |
| Borja, J | 1 |
| Galindo, PA | 1 |
| Feo, F | 1 |
| Cortina, P | 1 |
| Casanueva, T | 2 |
| Santos, O | 1 |
| Chang, HT | 1 |
| Mok, KT | 1 |
| Tzeng, WS | 1 |
| Suresh Kumar, G | 1 |
| Lipman, R | 1 |
| Cummings, J | 1 |
| Tomasz, M | 1 |
| Yamachika, T | 1 |
| Nakanishi, H | 1 |
| Inada, K | 1 |
| Tsukamoto, T | 1 |
| Kato, T | 1 |
| Fukushima, M | 1 |
| Inoue, M | 1 |
| Tatematsu, M | 1 |
| Yamaguchi, T | 1 |
| Yamaoka, N | 1 |
| Kitamura, K | 1 |
| Otsuji, E | 1 |
| Okamoto, K | 1 |
| Tsuruta, H | 1 |
| Yata, Y | 1 |
| Takahashi, T | 2 |
| Ayed, M | 1 |
| Ben Hassine, L | 1 |
| Ben Slama, R | 1 |
| Chelbi, N | 1 |
| Ghozzi, S | 1 |
| Drissi, H | 1 |
| Jemni, M | 1 |
| Chebil, M | 1 |
| Chopin, DK | 1 |
| Kubo, K | 1 |
| Arnaud, JP | 1 |
| Peyrat, PP | 1 |
| Konishi, I | 1 |
| Nanbu, K | 1 |
| Mandai, M | 1 |
| Tsuruta, Y | 1 |
| Kataoka, N | 1 |
| Nagata, Y | 1 |
| Mori, T | 1 |
| Naoe, Y | 1 |
| Kawamura, I | 1 |
| Inami, M | 1 |
| Matsumoto, S | 1 |
| Nishigaki, F | 1 |
| Tsujimoto, S | 1 |
| Manda, T | 1 |
| Shimomura, K | 1 |
| Butz, K | 1 |
| Whitaker, N | 1 |
| Denk, C | 1 |
| Ullmann, A | 1 |
| Geisen, C | 1 |
| Hoppe-Seyler, F | 1 |
| Fang, L | 1 |
| Igarashi, M | 1 |
| Leung, J | 1 |
| Sugrue, MM | 1 |
| Lee, SW | 1 |
| Aaronson, SA | 1 |
| Mantovani, F | 1 |
| Banks, L | 1 |
| van der Vange, N | 1 |
| Witkamp, AJ | 1 |
| Kaag, MM | 1 |
| Beijnen, JH | 1 |
| David-Pfeuty, T | 1 |
| Kunkeler, L | 1 |
| Nieboer, C | 1 |
| Bruynzeel, DP | 1 |
| Leder, GH | 1 |
| Pillasch, J | 1 |
| Kornmann, M | 1 |
| Danenberg, PV | 1 |
| Link, KH | 1 |
| Beaujard, AC | 1 |
| Caillot, JL | 1 |
| Cavaliere, F | 2 |
| Perri, P | 1 |
| Di Filippo, F | 2 |
| Giannarelli, D | 2 |
| Botti, C | 2 |
| Cosimelli, M | 2 |
| Tedesco, M | 2 |
| Principi, F | 1 |
| Laurenzi, L | 2 |
| Cavaliere, R | 2 |
| Aloe, L | 1 |
| Arcuri, E | 1 |
| Aromatario, C | 1 |
| Consolo, S | 1 |
| Callopoli, A | 1 |
| Di Angelo, P | 1 |
| Giunta, S | 1 |
| Rey, Y | 1 |
| Porcheron, J | 1 |
| Talabard, JN | 1 |
| Szafnicki, K | 1 |
| Balique, JG | 1 |
| Pestieau, SR | 1 |
| Neykov, K | 1 |
| Donkov, I | 1 |
| Mirchov, R | 1 |
| Kołodziejczyk, P | 1 |
| Rambo, TD | 1 |
| Fischer, M | 1 |
| Klahold, M | 1 |
| Wang, Y | 1 |
| Zhou, C | 1 |
| Jia, J | 1 |
| Huang, T | 1 |
| Kemp, EG | 1 |
| Harnett, AN | 1 |
| Chatterjee, S | 1 |
| Dhar, DK | 1 |
| Kubota, H | 1 |
| Yamanoi, A | 1 |
| Ono, T | 1 |
| Yashimura, H | 1 |
| Ohno, S | 1 |
| Tachibana, M | 1 |
| Kohno, H | 1 |
| Nagasue, N | 1 |
| Kiss, I | 1 |
| Marková, J | 1 |
| Tomásek, J | 1 |
| Vyzula, R | 1 |
| Válek, V | 1 |
| Boudný, J | 1 |
| Kala, Z | 1 |
| Hanke, I | 1 |
| Ostrízek, T | 1 |
| Leypold, J | 1 |
| Cascinu, S | 1 |
| Baldelli, AM | 1 |
| Catalano, V | 1 |
| Giordani, P | 1 |
| Beretta, GD | 1 |
| Silva, RR | 1 |
| Gasparini, G | 1 |
| Mari, D | 1 |
| Maisano, R | 1 |
| Salvagni, S | 1 |
| Barni, S | 1 |
| Labianca, R | 1 |
| Frontini, L | 1 |
| Curti, C | 1 |
| Catalano, G | 1 |
| Macdonald, AG | 1 |
| Nicolson, MC | 1 |
| Samuel, LM | 1 |
| Hutcheon, AW | 1 |
| Ahmed, FY | 1 |
| Karimine, N | 2 |
| Korenaga, D | 3 |
| Laurie, JA | 2 |
| Hahn, RG | 1 |
| Therneau, TM | 2 |
| Patel, SR | 1 |
| Mailliard, JA | 1 |
| Windschitl, HE | 2 |
| Twito, DI | 1 |
| Morton, RF | 1 |
| Krook, JE | 2 |
| Takamuku, K | 1 |
| Nanbara, S | 1 |
| Abe, R | 1 |
| Watanabe, D | 1 |
| Matsuoka, H | 1 |
| Coia, LR | 1 |
| Engstrom, PF | 1 |
| Paul, AR | 1 |
| Stafford, PM | 1 |
| Hanks, GE | 1 |
| Ozaki, H | 1 |
| Kinoshita, T | 1 |
| Kosuge, T | 1 |
| Shimada, K | 1 |
| Yamamoto, J | 1 |
| Egawa, S | 1 |
| Gelabert Mas, A | 1 |
| Vesa Llanes, J | 1 |
| Corominas, J | 1 |
| Arango Toro, O | 1 |
| Bielsa Galí, O | 1 |
| Lladó Carbonell, C | 1 |
| Tsekova, V | 1 |
| Koĭnov, K | 1 |
| Velikova, M | 1 |
| Suzuki, K | 1 |
| Nawata, S | 1 |
| Hirayama, T | 1 |
| Esato, K | 1 |
| Koh, J | 1 |
| Shiina, E | 1 |
| Hosoda, Y | 1 |
| Hashimoto, M | 1 |
| Yamamoto, O | 1 |
| Kubota, T | 3 |
| Enomoto, K | 1 |
| Abe, O | 3 |
| Matsuno, S | 1 |
| Hisano, H | 1 |
| Kobari, M | 1 |
| Akaishi, S | 1 |
| Watanabe, A | 1 |
| Haraguchi, M | 1 |
| Kakeji, Y | 1 |
| Orita, H | 1 |
| Rouëssé, J | 1 |
| Friedman, S | 1 |
| Mouriesse, H | 1 |
| Sarrazin, D | 1 |
| Spielmann, M | 1 |
| Wright, JC | 1 |
| Singh, P | 1 |
| Dharmalingam, SK | 1 |
| Tan, MK | 1 |
| Tan, CK | 1 |
| von der Maase, H | 1 |
| Okamura, T | 1 |
| Saito, A | 1 |
| Kusumoto, T | 1 |
| Sakaguchi, Y | 1 |
| Saku, M | 1 |
| Bruckner, HW | 1 |
| Kalman, J | 1 |
| Spigelman, M | 1 |
| Gorbaty, MI | 1 |
| Butwell, N | 1 |
| Storch, J | 1 |
| McKenna, A | 1 |
| Tveit, KM | 1 |
| Karlsen, KO | 1 |
| Fosså, SD | 1 |
| Flokkmann, A | 1 |
| Guldvog, I | 1 |
| Haffner, J | 1 |
| Treat, J | 1 |
| Falchuk, SC | 1 |
| Woolley, PV | 1 |
| Ahlgren, JD | 1 |
| Neefe, JR | 1 |
| Smith, FP | 1 |
| Macdonald, JS | 1 |
| Schein, PS | 1 |
| Arrizabalaga, M | 1 |
| Escribano, G | 1 |
| Gallardo, C | 1 |
| Inada, T | 2 |
| Inoue, S | 1 |
| Kuzuoka, M | 1 |
| Arisawa, Y | 1 |
| Suto, A | 1 |
| Kodaira, S | 1 |
| Ishibiki, K | 2 |
| Tonusin, A | 1 |
| Lorvidhaya, V | 1 |
| Punpae, P | 1 |
| Changwiwit, W | 1 |
| Charoeniam, V | 1 |
| Ployleumsang, D | 1 |
| Issariyodom, P | 1 |
| Kanzawa, F | 1 |
| Matsushima, Y | 1 |
| Hoshi, A | 1 |
| Shimizu, E | 1 |
| Saijo, N | 1 |
| Miyazawa, N | 1 |
| Nakada, M | 1 |
| Tsuyuki, K | 1 |
| Asanuma, F | 1 |
| Pasterz, R | 1 |
| Savaraj, N | 1 |
| Burgess, M | 1 |
| Brattain, MG | 1 |
| Willson, JK | 1 |
| Long, BH | 1 |
| Chakrabarty, S | 1 |
| Yeoman, LC | 1 |
| Stringfellow, DA | 1 |
| Jain, S | 1 |
| Seymour, AE | 1 |
| Uekado, Y | 1 |
| Shinka, T | 1 |
| Hirano, A | 1 |
| Ohkawa, T | 1 |
| Fukui, I | 1 |
| Sekine, H | 1 |
| Kihara, K | 1 |
| Yamada, T | 1 |
| Kawai, T | 1 |
| Washizuka, M | 1 |
| Ishiwata, D | 1 |
| Oka, K | 1 |
| Hosoda, K | 1 |
| Ikegami, S | 1 |
| Noguchi, S | 1 |
| Miyauchi, K | 1 |
| Nishizawa, Y | 1 |
| Koyama, H | 1 |
| Terasawa, T | 1 |
| Adhvaryu, SG | 1 |
| Rawal, UM | 1 |
| Patel, JV | 1 |
| Klöppel, G | 1 |
| Otto, U | 1 |
| Feddersen, I | 1 |
| Brachmann, W | 1 |
| Hubmann, H | 1 |
| Kaufmann, J | 1 |
| Knipper, W | 1 |
| Lantzius-Beninga, F | 1 |
| Monk, BJ | 1 |
| Surwit, EA | 1 |
| Alberts, DS | 1 |
| Graham, V | 1 |
| Yamamura, Y | 1 |
| Nakazato, H | 1 |
| Koike, A | 1 |
| Ichihashi, H | 1 |
| Kanno, A | 1 |
| Tanaka, S | 1 |
| Ito, T | 1 |
| Ban, K | 1 |
| Oshita, H | 1 |
| Fukata, D | 1 |
| Kashizuka, T | 1 |
| Hatoh, T | 1 |
| Kris, MG | 1 |
| Gralla, RJ | 1 |
| Wertheim, MS | 1 |
| Kelsen, DP | 1 |
| O'Connell, JP | 1 |
| Burke, MT | 1 |
| Fiore, JJ | 1 |
| Cibas, IR | 1 |
| Heelan, RT | 1 |
| Miller, TP | 1 |
| Vance, RB | 1 |
| Ahmann, FR | 1 |
| Rodney, SR | 1 |
| Eagan, RT | 1 |
| Rubin, J | 1 |
| Long, HJ | 1 |
| Schutt, AJ | 1 |
| Jett, JR | 1 |
| Fleming, TR | 1 |
| Dalton, RJ | 1 |
| Marschke, RF | 1 |
| Cullinan, SA | 1 |
| Everson, LK | 1 |
| Brunk, FS | 1 |
| Griffin, JP | 1 |
| Hagiwara, A | 1 |
| Lee, R | 1 |
| Ueda, T | 1 |
| Takeda, M | 1 |
| Itoh, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of UGN-101 on Ablation of Upper Urinary Tract Urothelial Carcinoma[NCT02793128] | Phase 3 | 71 participants (Actual) | Interventional | 2017-04-04 | Completed | ||
| Perioperative Systemic Therapy and Cytoreductive Surgery With HIPEC Versus Upfront Cytoreductive Surgery With HIPEC Alone for Isolated Resectable Colorectal Peritoneal Metastases: a Multicentre, Open-label, Parallel-group, Phase II-III, Randomised Superio[NCT02758951] | Phase 2/Phase 3 | 358 participants (Anticipated) | Interventional | 2017-06-01 | Recruiting | ||
| Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced Anal Canal Squamous Carcinoma Patients[NCT05060471] | Phase 2 | 27 participants (Anticipated) | Interventional | 2021-09-08 | Enrolling by invitation | ||
| A Phase 3, Multicenter, Double-Blind Randomized Study of Mitomycin, 5-Fluorouracil and IMRT Combined With or Without Anti-PD-1 in Patients With Locally Advanced Anal Canal Squamous Carcinoma[NCT05374252] | Phase 3 | 102 participants (Anticipated) | Interventional | 2022-05-07 | Recruiting | ||
| Intravesically Heated Thermo-chemotherapy With Mitomycin-C Prior to TURBT- Prospective Controlled Study[NCT02471547] | 300 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | |||
| Single Preoperative Intravesical Instillation of Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder Cancer: a Prospective Randomized Trial.[NCT01149174] | Phase 3 | 352 participants (Actual) | Interventional | 1994-01-31 | Completed | ||
| Intravesical Electromotive Mitomycin for High Risk Urothelial Non-muscle Invasive Bladder Cancer After Intravesical Bacillus Calmette-Guérin Failure[NCT04311580] | Phase 2 | 52 participants (Actual) | Interventional | 2000-01-01 | Completed | ||
| Effectiveness Evaluation of Mixed Gel of Hydrocortisone and Aluminium Phosphate Preventing Endoscopic Submucosal Dissection Postoperative Stenosis for Patients With Early Esophageal Cancer Invading More Than 2/3 Esophageal Perimeter[NCT03165344] | 66 participants (Actual) | Interventional | 2017-02-10 | Completed | |||
| BEV-IP: Perioperative Chemotherapy With Bevacizumab in Patients Undergoing Cytoreduction and Intraperitoneal Chemoperfusion for Colorectal Carcinomatosis[NCT02399410] | Phase 2 | 60 participants (Actual) | Interventional | 2015-12-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Clinical benefit for patients with partial response (PR) at the PDE visit. Clinical benefit endpoint was analyzed using the Intent-to-Treat (ITT) Analysis Set, including patients who achieved partial response at PDE Visit.Partial response at PDE visit will be defined dichotomously, similarly to the primary efficacy endpoint. For subjects with partial response at PDE visit, originally planned and actual treatments will be compared. (NCT02793128)
Timeframe: An average of 11 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| UGN-101 Mitomycin for Pyelocalyceal Solution | 8 |
"Durability of CR defined dichotomously as Success if CR was achieved at Primary Disease Evaluation (PDE) visit and remained at follow-up Visit 1, Visit 2 and Visit 3 (3, 6, 9 and 12 months post PDE visit), and Failure otherwise." (NCT02793128)
Timeframe: 3, 6, 9 and 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| UGN-101 Patients Evaluated 3 Months Post PDE | 35 |
| UGN-101 Patients Evaluated at 6 Months Post PDE | 33 |
| UGN-101 Patients Evaluated at 9 Months Post PDE | 28 |
| UGN-101 Patients Evaluated at 12 Months Post PDE | 23 |
"Cmax: maximum plasma concentration~Analysis of individual plasma concentration versus time profiles showed that at 6 hours post instillation, the plasma concentrations of all 6 patients were below 2 ng/mL, with the plasma concentration of one patient dropping below the LOQ (i.e., < 0.100 ng/mL). The mean Cmax was 6.24 ng/mL (range: 2.43 to 12.80 ng/mL). The highest individual observed Cmax value of 12.80 ng/mL was 187-fold and 40 fold lower than the observed Cmax level following an intravenous bolus dose of 30 mg or 10 mg mitomycin (2.4 μg/mL and 0.52 μg/mL, respectively) and is 31 fold lower than the threshold value of 400 ng/mL for myelosuppression observed with mitomycin." (NCT02793128)
Timeframe: Blood samples were collected at 0 minutes (pre-dose) and 30 minutes, 1, 2, 3, 4, 5, and 6 hours following the first instillation of UGN-101
| Intervention | ng/mL (Mean) |
|---|---|
| Pharmacokinetic Population | 6.24 |
"Half-life (t½): terminal half-life~The mean apparent t½ following instillation of mitomycin into the upper urinary tract (UUT) was 1.27 hours (76 minutes), which was longer than the true t½ of mitomycin following a 30 mg bolus injection (mean t½ value of approximately 17 minutes). The apparent t½ demonstrates that UGN-101 dissolved gradually, resulting in prolonged exposure of mitomycin following local instillation into the UUT." (NCT02793128)
Timeframe: Blood samples were collected at 0 minutes (pre-dose) and 30 minutes, 1, 2, 3, 4, 5, and 6 hours following the first instillation with UGN-101
| Intervention | Hours (Number) |
|---|---|
| Pharmacokinetic Population | 1.27 |
"Tmax: time to maximum plasma concentration~Analysis of individual plasma concentration versus time profiles showed that at 6 hours post instillation, the plasma concentrations of all 6 patients were below 2 ng/mL, with the plasma concentration of one patient dropping below the LOQ (i.e., < 0.100 ng/mL).~The mean Cmax was 6.24 ng/mL (range: 2.43 to 12.80 ng/mL), and the Tmax was 1.79 hours (range: 0.50 to 5.17 hours) after instillation. The highest individual observed Cmax value of 12.80 ng/mL was 187-fold and 40 fold lower than the observed Cmax level following an intravenous bolus dose of 30 mg or 10 mg mitomycin (2.4 μg/mL and 0.52 μg/mL, respectively) and is 31 fold lower than the threshold value of 400 ng/mL for myelosuppression observed with mitomycin." (NCT02793128)
Timeframe: Blood samples were collected at 0 minutes (pre-dose) and 30 minutes, 1, 2, 3, 4, 5, and 6 hours following the first instillation with UGN-101
| Intervention | Hours (Mean) |
|---|---|
| Pharmacokinetic Population | 1.79 |
"Continuously: Duration of CR or time-to-recurrence since the Primary Disease Evaluation (PDE) Visit (i.e., time in days from the visit at which CR was determined until recurrence or censoring). This endpoint served as the main long-term durability endpoint. Dichotomously: Success if CR was still present at the 12 month post-PDE Visit (at Follow-Up Visit 4), and Failure otherwise. This endpoint served as a supportive long-term durability endpoint." (NCT02793128)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| UGN-101 Mitomycin for Pyelocalyceal Solution | 23 |
"The primary efficacy endpoint was the number of patients attaining complete response (CR) at the end of the treatment period (Primary Disease Evaluation (PDE) visit). The CR was defined dichotomously as Success if CR was confirmed at PDE visit (or relevant follow-up), and Failure otherwise." (NCT02793128)
Timeframe: An average of 11 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| UGN-101 Mitomycin for Pyelocalyceal Solution | 42 |
Treatment-emergent AEs were most frequently reported from the Renal and urinary disorders system organ class (SOC), 59 (83.1%) patients, as expected, given the underlying indication of low grade (LG) Upper tract urothelial carcinoma (UTUC) in the study population, chemotherapeutic drug in a gel matrix instilled in the upper urinary tract (UUT), and the study procedure of treatment instillation via a ureteral catheter. The toxicity within the upper urinary tract was considered consistent with the disease under study and the mode of administration of UGN-101. Most events in the Renal and urinary disorders SOC were mild to moderate in severity and resolved. No new risks were identified and the overall safety profile was consistent with the known safety profile of endoscopic administration of intravesical mitomycin and of mitomycin. Overall, based on the safety and efficacy results to date, the benefit-risk profile of UGN-101 is favorable for the treatment of LG-UTUC. (NCT02793128)
Timeframe: Through study completion, an average of 15 months
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Treatment-emergent Adverse Events (TEAEs) | TEAEs related to study drug | TEAEs related to study procedure | TEAEs related to study drug or preocedure | Serious Adverse Events (SAE) | SAEs related to study drug or procedure | |
| UGN-101 Mitomycin for Pyelocalyceal Solution | 67 | 52 | 55 | 61 | 28 | 19 |
12 reviews available for mitomycin and Carcinoma, Anaplastic
| Article | Year |
|---|---|
[Medical treatment of bladder carcinoma].
Topics: Aminolevulinic Acid; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BC | 2013 |
Partial hepatectomy for liver metastases from nasopharyngeal carcinoma: a comparative study and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoembolization, Th | 2014 |
Pharmacokinetics of intraperitoneal mitomycin C.
Topics: Area Under Curve; Biological Availability; Carcinoma; Chemotherapy, Adjuvant; Dose-Response Relation | 2003 |
Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Gastro | 2004 |
Chemotherapy of hormonally unresponsive prostatic carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carmustine; Cispla | 1984 |
Bolus mitomycin C and 5-FU with sequential radiation for poor-prognosis locally advanced cervical cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Carcinoma; Combined Modality Therapy; | 1996 |
Combined infusional chemotherapy and radiation for esophageal carcinoma: a review.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Clinica | 1995 |
Individualized chemotherapeutic regimen for each histological subtype of ovarian carcinoma.
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; C | 1997 |
[Intravesical instillation in the treatment of superficial tumors of the bladder].
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma; Carcinoma, Transi | 1998 |
Update in cancer chemotherapy, Part III: Lung cancer, Part 1.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Bleomycin; Carcinoma; C | 1985 |
Management of peritoneal carcinomatosis.
Topics: Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Fluorouracil; Humans; Injections, Intra | 1989 |
[A case of an exogastric developing-type carcinoma of the stomach and a review of thirty nine cases reported in Japan].
Topics: Antigens, Neoplasm; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy P | 1988 |
49 trials available for mitomycin and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma; Female; Humans; Hydrogels; Male; Middle Aged; Mitomyci | 2022 |
Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma; Drug Carriers; Drug Compound | 2020 |
The HELENA study: Hexvix
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Antineoplastic Ag | 2021 |
Colorectal peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: the experience of a tertiary Asian center.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Cancer, Regional Perf | 2015 |
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for patients with peritoneal carcinomatosis from colorectal cancer: a phase II study from a Chinese center.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; China; Cisplatin; | 2014 |
Routine second-look after surgical treatment of colonic peritoneal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemo | 2015 |
Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I).
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma; Fluorouracil; Follow-Up S | 2010 |
Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I).
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma; Fluorouracil; Follow-Up S | 2010 |
Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I).
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma; Fluorouracil; Follow-Up S | 2010 |
Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I).
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma; Fluorouracil; Follow-Up S | 2010 |
Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial).
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma; Female; Humans; Kidney Neopl | 2011 |
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; | 2011 |
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; | 2011 |
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; | 2011 |
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; | 2011 |
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; | 2011 |
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; | 2011 |
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; | 2011 |
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; | 2011 |
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; | 2011 |
Locoregional mitomycin C injection for esophageal stricture after endoscopic submucosal dissection.
Topics: Aged; Carcinoma; Catheterization; Deglutition Disorders; Dissection; Esophageal Neoplasms; Esophagea | 2012 |
A phase I trial of thermal sensitization using induced oxidative stress in the context of HIPEC.
Topics: Adult; Aged; Antineoplastic Agents; Appendiceal Neoplasms; Carcinoma; Colonic Neoplasms; Female; Hum | 2013 |
Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis.
Topics: Antibiotics, Antineoplastic; Carcinoma; Combined Modality Therapy; Female; Humans; Hyperthermia, Ind | 2003 |
[Cytoreductive surgery with intraperitoneal chemotherapy in patients with colon cancer and peritoneal carcinomatosis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic Neoplasms; Combined | 2003 |
Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from colon adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Differe | 2003 |
Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer.
Topics: Adult; Aged; Biopsy, Needle; Carcinoma; Chemotherapy, Cancer, Regional Perfusion; Combined Modality | 2004 |
Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Combined Mo | 2004 |
Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy coo
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined | 2005 |
Inoperable oropharyngeal carcinoma treated with concomitant irradiation, mitomycin C and bleomycin - long term results.
Topics: Adult; Aged; Bleomycin; Carcinoma; Combined Modality Therapy; Disease-Free Survival; Dose-Response R | 2005 |
Long-term survival of peritoneal carcinomatosis of colorectal origin.
Topics: Antibiotics, Antineoplastic; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Female; Fol | 2005 |
Combining cisplatin and mitomycin with radiotherapy in anal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2007 |
Mitomycin C and etoposide in advanced colorectal carcinoma. A clinical and in vitro experience that focuses the problem of schedule dependence in combination therapy.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2007 |
Chemotherapy of hormonally unresponsive prostatic carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carmustine; Cispla | 1984 |
[Long-term results of intravesical prevention of recurrence with mitomycin C and adriamycin in patients with superficial bladder cancer].
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy P | 1994 |
Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Doxorubicin; Epir | 1994 |
Mitomycin "C" and vinorelbine as second line chemotherapy for metastatic breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Drug Admin | 1994 |
Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group Study.
Topics: Biliary Tract Neoplasms; Carcinoma; Female; Gallbladder Neoplasms; Humans; Male; Middle Aged; Mitomy | 1993 |
Bolus mitomycin C and 5-FU with sequential radiation for poor-prognosis locally advanced cervical cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Carcinoma; Combined Modality Therapy; | 1996 |
Phase I and pharmacokinetic study of KW-2149 given by 24 hours continuous infusion.
Topics: Antineoplastic Agents; Carcinoma; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drugs, Inv | 1995 |
Simultaneous radiochemotherapy for recurrent and metastatic breast carcinoma: evaluation of two treatment concepts.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Ant | 1996 |
5-Fluorouracil, epirubicin, and mitomycin C versus 5-fluorouracil, epirubicin, mitomycin C, and leucovorin in advanced gastric carcinoma. A randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Epirubicin; Female; Fluorour | 1996 |
Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: a phase II trial.
Topics: Abdominal Pain; Adult; Aged; Alkaline Phosphatase; Angiography; Antimetabolites, Antineoplastic; Ant | 1997 |
Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma; Combined Modality Therapy; Equipment Design; Fe | 2000 |
[Peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemohyperthermia].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma; Chemotherapy, Cancer, Regional Perfusion; | 2000 |
Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic N | 2000 |
The relationship between improved prognosis in gastric cancer patients in the last 25 years and changing methods of surgical and combined treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcino | 2000 |
Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma; | 2001 |
Accelerated hyperfractionated radiotherapy with concurrent chemotherapy in locally advanced nasopharyngeal carcinoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Dose | 2001 |
Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer: a low cost effective regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cost-Benefit Anal | 2002 |
A phase II study of mitomycin C, cisplatin and continuous infusion 5-fluorouracil (MCF) in the treatment of patients with carcinoma of unknown primary site.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Female; Fluoroura | 2002 |
Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil.
Topics: Acid Phosphatase; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Doxorubicin; Fluo | 1992 |
A trial of adjuvant chemoimmunotherapy with mitomycin C and OK-432 for stage III gastric carcinoma.
Topics: Carcinoma; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Mitomycin; Picibanil; Stoma | 1992 |
Chemotherapy-radiotherapy combination in the treatment of carcinoma of the cervix.
Topics: Adult; Aged; Bleomycin; Carcinoma; Combined Modality Therapy; Female; Humans; Middle Aged; Mitomycin | 1985 |
Sequential instillation therapy with mitomycin C and adriamycin for superficial bladder tumors.
Topics: Administration, Intravesical; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma | 1987 |
Cytostatic intravesical instillation in patients with superficial bladder carcinoma for the prevention of recurrent tumors.
Topics: Administration, Intravesical; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clini | 1988 |
[A randomized controlled trial comparing short-term MF chemotherapy with MF plus long-term HCFU chemotherapy as an adjuvant to a curative resection of stomach cancer: Mifurol Study Group for Stomach Cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as | 1988 |
Trial of the combination of mitomycin, vindesine, and cisplatin in patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Clinical Trials as Topic; Fema | 1986 |
Extensive non-small cell lung cancer treated with mitomycin, cisplatin, and vindesine (MiPE): a Southwest Oncology Group Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Clinical Trials as Topic | 1986 |
Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. A randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Clinical Trials a | 1987 |
A controlled evaluation of combined 5-fluorouracil, doxorubicin, and mitomycin C (FAM) for the treatment of advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S | 1985 |
148 other studies available for mitomycin and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Potent antitumor bifunctional DNA alkylating agents, synthesis and biological activities of 3a-aza-cyclopenta[a]indenes.
Topics: Animals; Antineoplastic Agents, Alkylating; Aza Compounds; Breast Neoplasms; Carcinoma; Cell Cycle; | 2009 |
Effects of Mitomycin-C and 5-Fluorouracil on Ocular Adnexal Sebaceous Carcinoma Cells.
Topics: Carcinoma; Cell Survival; Cells, Cultured; Eye Neoplasms; Fluorouracil; Humans; Mitomycin | 2022 |
Toxicity profile of chemotherapy agents used in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neop | 2020 |
Delta peritoneal cancer index (ΔPCI): A new dynamic prognostic parameter for survival in patients with colorectal peritoneal metastases.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma; Colorectal Neoplasms; Cytoreduction Surgical Procedure | 2020 |
Identification of pharmacogenetic biomarkers for efficacy of cytoreductive surgery plus hyperthermic intraperitoneal mitomycin C in patients with colorectal peritoneal metastases.
Topics: Aged; Alleles; Antibiotics, Antineoplastic; Carcinoma; Colorectal Neoplasms; Cytochrome P-450 Enzyme | 2020 |
Intraperitoneal collagenase as a novel therapeutic approach in an experimental model of colorectal peritoneal carcinomatosis.
Topics: Animals; Antibiotics, Antineoplastic; Carcinoma; Collagenases; Colorectal Neoplasms; Disease Models, | 2021 |
Individual learning curve of cytoreductive surgery for peritoneal metastasis from colorectal cancer: A process with an impact on survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cholecystectomy; Colectomy; | 2021 |
Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Breast Neoplasms; Carcinoma; Case-Control Studies; Cell | 2017 |
Current practice in cytoreductive surgery and HIPEC for metastatic peritoneal disease: Spanish multicentric survey.
Topics: Antineoplastic Agents; Carcinoma; Cardiac Output; Cisplatin; Colorectal Neoplasms; Cytoreduction Sur | 2018 |
Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC.
Topics: Aged; Antineoplastic Agents; Carcinoma; Cohort Studies; Colorectal Neoplasms; Combined Modality Ther | 2018 |
CEA to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with colorectal cancer peritoneal carcinomatosis undergoing cytoreduction surgery and intraperitoneal chemotherapy: A retrospective cohort study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Carcinoma; Cohort St | 2018 |
Hypovolemic shock after pelvic radiotherapy. A rare combination leading to a devastating complication.
Topics: Aged; Anaphylaxis; Anus Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Chemoradiotherapy; Colon, Si | 2019 |
The investigation of a traditional Chinese medicine, Guizhi Fuling Wan (GFW) as an intravesical therapeutic agent for urothelial carcinoma of the bladder.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma; Cell Cycle; Cell Lin | 2013 |
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: the Danish experience.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Appendiceal Neoplasms; Carcinoma; Colorectal Neoplasms; Co | 2013 |
A multicellular 3D heterospheroid model of liver tumor and stromal cells in collagen gel for anti-cancer drug testing.
Topics: Animals; Antibiotics, Antineoplastic; Carcinoma; Cell Line; Coculture Techniques; Collagen; Doxorubi | 2013 |
Impact of hyperthermic intraperitoneal chemotherapy on Hsp27 protein expression in serum of patients with peritoneal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Agents; C-Reactive Protein; Carcinoma; Cisplatin; Combined Modality Ther | 2013 |
The benefit of intraperitoneal chemotherapy for the treatment of colorectal carcinomatosis.
Topics: Animals; Carcinoma; Cell Line, Tumor; Cell Survival; Chemotherapy, Cancer, Regional Perfusion; Color | 2013 |
Controversy and consensus on the management of patients with pseudomyxoma peritonei.
Topics: Carcinoma; Combined Modality Therapy; Diagnosis, Differential; Humans; Mitomycin; Neoplasm Staging; | 2013 |
Repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: analysis of survival outcomes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Carboplatin; Car | 2013 |
HPMA copolymer conjugates of DOX and mitomycin C for combination therapy: physicochemical characterization, cytotoxic effects, combination index analysis, and anti-tumor efficacy.
Topics: Acrylamides; Animals; Antineoplastic Agents; Carcinoma; Carcinoma, Lewis Lung; Cell Line, Tumor; Cyt | 2013 |
Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: a prospective study of 216 patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Cohort Stu | 2014 |
Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients.
Topics: Abdominal Neoplasms; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplast | 2014 |
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Blood Transfusio | 2014 |
Recovery from mitomycin-induced pulmonary arterial hypertension.
Topics: Antineoplastic Agents; Anus Neoplasms; Bosentan; Carcinoma; Endothelin Receptor Antagonists; Female; | 2014 |
Feasibility of adjuvant laparoscopic hyperthermic intraperitoneal chemotherapy in a short stay setting in patients with colorectal cancer at high risk of peritoneal carcinomatosis.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Cohort Studies; Colorec | 2014 |
[Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal and appendiceal origin].
Topics: Antibiotics, Antineoplastic; Antineoplastic Protocols; Appendiceal Neoplasms; Carcinoma; Chemotherap | 2014 |
Feeding tube placement during cytoreductive surgery and heated intraperitoneal chemotherapy does not improve postoperative nutrition and is associated with longer length of stay and higher readmission rates.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Canc | 2016 |
Metabolic tumour volume of anal carcinoma on (18)FDG PET/CT before combined radiochemotherapy is the only independant determinant of recurrence free survival.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2016 |
Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with peritoneal metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Colorectal Neoplasms; Combined | 2016 |
Hyperfractionated accelerated radiotherapy versus conventional fractionation both combined with chemotherapy in patients with locally advanced head and neck carcinomas: a retrospective analysis of a monoinstitutional series.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Therapy; Dose Fra | 2009 |
Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Carcinoma; CD40 Ligand; Cell Line, Tumor; C | 2009 |
Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in the treatment of peritoneal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality | 2009 |
[Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC): evaluation, prevention and policies to avoid occupational exposure for operating room personnel].
Topics: Air Pollutants, Occupational; Antineoplastic Agents; Camptothecin; Carcinoma; Chemotherapy, Cancer, | 2009 |
Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Ap | 2011 |
Successful remission of extensive liver metastases in a breast cancer patient with acute liver failure using a combined chemotherapy regimen with mitomycin, folinate, and 5-fluorouracil (Mi/Fo/FU).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Female; Fluorouracil; H | 2010 |
Postoperative intravesical therapy to prevent bladder tumor recurrence: are we ready to listen yet?
Topics: Antibiotics, Antineoplastic; Carcinoma; Female; Humans; Kidney Neoplasms; Male; Mitomycin; Nephrecto | 2011 |
Bladder cancer: neoadjuvant is new again.
Topics: Antibiotics, Antineoplastic; Carcinoma; Cystectomy; Female; Humans; Male; Mitomycin; Urinary Bladder | 2011 |
Intraoperative versus early postoperative intraperitoneal chemotherapy after cytoreduction for colorectal peritoneal carcinomatosis: an experimental study.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Colonic | 2012 |
[Intraabdominal chemotherapy of prevailing forms of colon cancer].
Topics: Abdominal Cavity; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic Neoplasms; Fluo | 2011 |
Rosiglitazone reverses mitomycin C resistance in human gastric cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Antibiotics, Antineoplastic; Apoptosis; ATP Binding Cassette T | 2012 |
Electromotive administration of mitomycin.
Topics: Antibiotics, Antineoplastic; Carcinoma; Cystectomy; Female; Humans; Male; Mitomycin; Urinary Bladder | 2011 |
A human Fab-based immunoconjugate specific for the LMP1 extracellular domain inhibits nasopharyngeal carcinoma growth in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Binding Sites; Carcinoma; Cell Line, Tumor; Cell Prolifer | 2012 |
Re: Tim O'Brien, Eleanor Ray, Rajinder Singh, Bola Coker, Ralph Beard, British Association of Urological Surgeons Section of Oncology. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospecti
Topics: Antibiotics, Antineoplastic; Carcinoma; Female; Humans; Kidney Neoplasms; Male; Mitomycin; Nephrecto | 2012 |
A novel LMP1 antibody synergizes with mitomycin C to inhibit nasopharyngeal carcinoma growth in vivo through inducing apoptosis and downregulating vascular endothelial growth factor.
Topics: Animals; Antibodies; Apoptosis; Carcinoma; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Dr | 2012 |
Velopharyngeal and choanal stenosis after radiotherapy for nasopharyngeal carcinoma.
Topics: Antibiotics, Antineoplastic; Carcinoma; Cicatrix; Constriction, Pathologic; Endoscopy; Female; Human | 2013 |
Mitomycin C induces apoptosis and caspase-8 and -9 processing through a caspase-3 and Fas-independent pathway.
Topics: Antibiotics, Antineoplastic; Apoptosis; Breast Neoplasms; Carcinoma; Caspase 3; Caspase 7; Caspase 8 | 2002 |
Intraoperative modality of treatment for peritoneal carcinomatosis: use of hyperthermic interperitoneal chemoperfusion.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Carcinoma; Combined Modality Therapy; Female; | 2002 |
Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis.
Topics: Activities of Daily Living; Adult; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Cance | 2003 |
Salvage chemotherapy with a combination of irinotecan hydrochloride and mitomycin C in platinum- and paclitaxel-resistant epithelial ovarian cancer: case reports.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Carcinoma; Cispl | 2003 |
[Morphological and biochemical changes in ascites tumor cells in mice following administration of mitomycin C].
Topics: Animals; Ascites; Carcinoma; Carcinoma, Ehrlich Tumor; DNA; DNA, Neoplasm; Mice; Mitomycin; Mitomyci | 1962 |
Comparative studies of antitumor activities of mitomycin C and 6-mercaptopurine.
Topics: Animals; Antineoplastic Agents; Carcinoma; Mercaptopurine; Mitomycin; Sarcoma, Experimental | 1961 |
Experimental treatment of cancer with mitomycin C alone or in combination with carzinophilin.
Topics: Antimicrobial Cationic Peptides; Antineoplastic Agents; Carcinoma; Humans; Mitomycin; Neoplasms; Pep | 1961 |
[ON THE ANTICANCER ACTION OF BAMBOO EXTRACT].
Topics: Animals; Antineoplastic Agents; Carcinoma; Carcinoma, Ehrlich Tumor; Ion Exchange Resins; Mechloreth | 1963 |
A TECHNIQUE FOR PROLONGED CONTINUOUS INTRA-ARTERIAL INFUSION IN RABBITS. METHOD FOR THE COMPARISON OF THE EFFECTS OF ANTICANCER DRUGS BY CONTINUOUS INTRA-ARTERIAL INFUSION IN THE RABBIT BEARING VX2 CARCINOMAS IN EACH HIND LIMB.
Topics: Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Femoral Artery; Gangrene; Infusions, Int | 1964 |
EFFECT OF MITOMYCIN C ON NUCLEIC ACID BIOSYNTHESIS IN EHRLICH ASCITES TUMOR CELLS.
Topics: Animals; Carcinoma; Carcinoma, Ehrlich Tumor; DNA; DNA, Neoplasm; Metabolism; Methionine; Mice; Mito | 1964 |
Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma.
Topics: Antibiotics, Antineoplastic; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Disease-Fre | 2004 |
Fatal arrhythmia following intraoperative continuous hyperthermic peritoneal perfusion chemotherapy.
Topics: Abdominal Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, | 2003 |
Chemoembolization of liver metastasis from breast carcinoma.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Carcin | 2004 |
Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; | 2004 |
[Multidisciplinary treatment of recurrent epithelial ovarian carcinoma and prognostic analysis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Comb | 2004 |
[Mitomycin C: prevention and treatment of anterior glottic synechia].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma; Female; Glottis; Humans; Laryngeal Neoplasms; L | 2004 |
Treatment of peritoneal carcinomatosis in patients with digestive cancers with combination of intraperitoneal hyperthermia and mitomycin C.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Ascites; Carcinoma; Combined Modality Therapy; Female; Gas | 2004 |
hTERT antagonizes p53-induced apoptosis independently of telomerase activity.
Topics: Apoptosis; Burkitt Lymphoma; Carcinoma; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; DNA-Bind | 2005 |
Treatment of peritoneal carcinomatosis from colorectal cancer by cytoreductive surgery and hyperthermic perioperative intraperitoneal chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined C | 2005 |
Maitake D-Fraction enhances antitumor effects and reduces immunosuppression by mitomycin-C in tumor-bearing mice.
Topics: Animals; Antibiotics, Antineoplastic; Biomarkers, Tumor; Carcinoma; Cell Line, Tumor; Dose-Response | 2005 |
Percutaneous sequential bacillus Calmette-Guèrin and mitomycin C for panurothelial carcinomatosis.
Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma; Drug Therapy, Combinati | 2005 |
Effects of low-dose warfarin and regional chemotherapy on survival in patients with pancreatic carcinoma.
Topics: Antibiotics, Antineoplastic; Anticoagulants; Carcinoma; Deoxycytidine; Dose-Response Relationship, D | 2006 |
[Anesthetic management for scheduled peritonectomy and hyperthermic intraperitoneal chemotherapy in 20 patients].
Topics: Adult; Aged; Analgesia, Epidural; Anesthesia, General; Anesthesia, Inhalation; Anesthesia, Intraveno | 2006 |
Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma; Chemothe | 2007 |
Long-term survival of resectable subset after induction chemotherapy in patients with locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Car | 2008 |
Coordinated chemoradiation therapy with genital preservation for the treatment of primary invasive carcinoma of the male urethra.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Cohort Studies; Combined Modality | 2008 |
Advanced gastric cancer with or without peritoneal carcinomatosis treated with hyperthermic intraperitoneal chemotherapy: a single western center experience.
Topics: Antineoplastic Agents; Carcinoma; Cisplatin; Drug Therapy, Combination; Female; Follow-Up Studies; F | 2008 |
[Nasopharyngeal carcinoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Carci | 1984 |
Combination chemotherapy for metastatic carcinoma of the ampulla of Vater--report of three cases.
Topics: Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Common Bile Duct | 1984 |
Late results of postoperative long-term cancer chemotherapy for the gastric cancer patients subjected to curative resection.
Topics: Antibiotics, Antineoplastic; Carcinoma; Dose-Response Relationship, Drug; Drug Administration Schedu | 1983 |
Pharmacokinetics of mitomycin C in non-oat cell carcinoma of the lung.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chromatograp | 1984 |
Intra-arterial administration of heated albumin microspheres containing mitomycin C to rabbits with VX-2 tumor.
Topics: Animals; Carcinoma; Cell Line; Delayed-Action Preparations; Infusions, Intra-Arterial; Kinetics; Mal | 1984 |
Combination chemoimmunotherapy for advanced gastric carcinoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Ca | 1984 |
Antitumor activity of 7-n-(p-hydroxyphenyl)-mitomycin C in experimental tumor systems.
Topics: Animals; Carcinoma; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Fibrosarcoma; Le | 1981 |
Antitumor effect of arterial administration of a medium-chain triglyceride solution of an angiogenesis inhibitor, TNP-470, in rabbits bearing VX-2 carcinoma.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Caprylates; Ca | 1995 |
Immunohistochemical features of HLA-DR antigen expression and lymphoid infiltrates in gastric carcinoma after low-dose interleukin-2 and mitomycin C.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Drug Administration Schedule; Femal | 1995 |
Long-term follow-up of patients with epithelial carcinoma of the ovary.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cyclophosphamide; Cytarabine; | 1994 |
[The prognostic factors following the simultaneous radiochemotherapy of anal canal carcinoma in a multicenter series of 139 patients].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1994 |
Expression of glutathione S-transferase-pi and sensitivity of human gastric cancer cells to cisplatin.
Topics: Aclarubicin; Animals; Carbazilquinone; Carcinoma; Cell Nucleus; CHO Cells; Cisplatin; Cricetinae; Cy | 1994 |
Characterization of a human bladder cancer cell line selected for resistance to mitomycin C.
Topics: Antineoplastic Agents; Carcinoma; Catalase; Cell Cycle; Cell Survival; DNA Damage; Drug Resistance; | 1994 |
[Fibrino-necrotic ulcers in endovesical chemoprophylaxis in superficial bladder carcinoma: our case histories].
Topics: Administration, Intravesical; Aged; Carcinoma; Combined Modality Therapy; Female; Fibrosis; Follow-U | 1994 |
Secondary leukaemia after MMM combined modality therapy for breast carcinoma.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; F | 1993 |
Intraperitoneal chemotherapy for treatment and prevention of peritoneal carcinomatosis and sarcomatosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Doxoru | 1994 |
[Intraperitoneal chemo-hyperthermia in the treatment of peritoneal carcinomatosis of ovarian origin. Initial cases, physiopathologic data].
Topics: Aged; Carcinoma; Cisplatin; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Inject | 1993 |
Concurrent preoperative chemotherapy with 5-fluorouracil and mitomycin C and radiotherapy (FUMIR) followed by limited surgery in locally advanced and recurrent vulvar carcinoma.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 1996 |
A prospective evaluation of the treatment of primary or metastatic liver carcinoma with hepatic arterial infusion chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 1996 |
"MECCA": a developmental, dose-intensive, non-cross-resistant platinum-based chemotherapy for advanced ovarian cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Disease-Fr | 1996 |
Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery.
Topics: Carcinoma; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Male; Middle Aged; Mito | 1997 |
Allergic contact dermatitis from mitomycin C.
Topics: Administration, Intravesical; Carcinoma; Dermatitis, Allergic Contact; Female; Humans; Middle Aged; | 1997 |
Induction intraarterial chemotherapy for T4 breast cancer through an implantable port-catheter system.
Topics: Adult; Aged; Ambulatory Care; Angiography, Digital Subtraction; Antibiotics, Antineoplastic; Antineo | 1997 |
Mitomycin C-DNA adducts generated by DT-diaphorase. Revised mechanism of the enzymatic reductive activation of mitomycin C.
Topics: Alkylation; Animals; Antibiotics, Antineoplastic; Carcinoma; DNA Adducts; DNA, Bacterial; Hydrogen-I | 1997 |
A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance.
Topics: Antibiotics, Antineoplastic; Antibodies; Biomarkers, Tumor; Carcinoma; Chemotherapy, Adjuvant; Chi-S | 1998 |
Changes in expression of the antigen recognized by monoclonal antibody A7 in human pancreatic carcinoma cells following exposure to anticancer agents.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antigens, Neoplasm; Carcinoma; Cell Count; Cell | 1998 |
[Results of BCG in the treatment of pTa and pT1 bladder tumors. Evaluation of a long protocol using 75 mg of Pasteur strain BCG].
Topics: Actuarial Analysis; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antin | 1998 |
Effect of Maitake D-fraction on cancer prevention.
Topics: Administration, Oral; Animals; Antibiotics, Antineoplastic; Anticarcinogenic Agents; Antineoplastic | 1997 |
[Perspectives in the treatment of peritoneal carcinosis].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 1997 |
[Intraperitoneal chemo-hyperthermia with mitomycin C in cancer of the stomach with peritoneal carcinosis].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Ascites; Carcinoma; Cause of Death; Chemotherapy, Cancer, | 1997 |
Tumor response to neoadjuvant chemotherapy correlates with the expression of P-glycoprotein and PCNA but not GST-pi in the tumor cells of cervical carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Membe | 1998 |
Anti-cachectic effect of FK317, a novel anti-cancer agent, in colon26 and LX-1 models in mice.
Topics: Adenocarcinoma; Adipose Tissue; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Blood G | 1998 |
Induction of the p53-target gene GADD45 in HPV-positive cancer cells.
Topics: Carcinoma; Cell Division; Cisplatin; DNA Damage; Female; GADD45 Proteins; Gamma Rays; Gene Expressio | 1999 |
p21Waf1/Cip1/Sdi1 induces permanent growth arrest with markers of replicative senescence in human tumor cells lacking functional p53.
Topics: Apoptosis; beta-Galactosidase; Biomarkers; Carcinoma; CDC2-CDC28 Kinases; Cell Division; Cellular Se | 1999 |
Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines.
Topics: Acetylcysteine; Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Breast Neoplasms; Carcinoma; C | 1999 |
[Hyperthermic intra-peritoneal chemotherapy (HIPEC) in patients with peritoneal pseudomyxoma or peritoneal metastases of colorectal carcinoma; good preliminary results from the Netherlands Cancer Institute].
Topics: Antibiotics, Antineoplastic; Carcinoma; Colorectal Neoplasms; Disease-Free Survival; Dose-Response R | 1999 |
Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells.
Topics: Blotting, Western; Breast Neoplasms; Carcinoma; CDC2-CDC28 Kinases; Cell Cycle; Cell Death; Cell Lin | 1999 |
Type III and type IV hypersensitivity reactions due to mitomycin C.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Dermatitis, Exfoliative; | 2000 |
Theoretical considerations and in vitro concentration response studies with two human colorectal carcinoma cell lines. The rational experimental base for clinical studies in regional chemotherapy.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2000 |
Treatment of peritoneal carcinomatosis with intent to cure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Colorectal Neoplasms; Combined | 2000 |
Peritonectomy and hyperthermic antiblastic perfusion in the treatment of peritoneal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Cancer, Region | 2000 |
[Intravesical chemotherapy with mitomycin C after TUR for superficial bladder carcinoma].
Topics: Administration, Intravesical; Aged; Carcinoma; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Hu | 1999 |
Endoscopic Nd:YAG laser therapy combined with local chemotherapy of superficial carcinomas of the oesophagus and gastric cardia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cardia; Combined Modality Th | 2001 |
Preoperative topical and intraoperative local mitomycin C adjuvant therapy in the management of ocular surface neoplasias.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma; Che | 2002 |
Selective approaches to gastric cancer patients with liver metastases: role of liver-directed chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Doxorubicin; Fluorouracil; Humans; Infusi | 2001 |
[Personal experience with intra-arterial locoregional chemotherapy of liver metastases from colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Doxorubicin; Female | 2001 |
Immunohistochemical analysis of lymphocyte subsets infiltrating gastric carcinoma after mitomycin C administration.
Topics: Aged; Carcinoma; CD4 Antigens; CD8 Antigens; Female; Humans; Immunohistochemistry; Lymphocyte Subset | 1992 |
Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; | 1991 |
Evidence of effective multidisciplinary treatment for resectable pancreatic cancer from the viewpoint of the CA19-9 level.
Topics: Aged; Antigens, Tumor-Associated, Carbohydrate; Carcinoma; Combined Modality Therapy; Female; Humans | 1991 |
[Eosinophilic cystitis as a special form of response to mitomycin C. Analysis and comments on our cases].
Topics: Administration, Intravesical; Antigen-Antibody Complex; Carcinoma; Combined Modality Therapy; Cystit | 1991 |
[The adjuvant chemotherapy of patients with colorectal carcinoma (preliminary report)].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adju | 1991 |
[Thymic undifferentiated carcinoma with resection of superior vena cava: report of a case].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therap | 1991 |
Changes in the hormone receptors of human breast carcinoma xenografts in nude mice by treatment with cytotoxic agents.
Topics: Animals; Breast Neoplasms; Carcinoma; Cyclophosphamide; Female; Humans; Mice; Mice, Inbred BALB C; M | 1990 |
Growth-inhibitory effect of combination chemotherapy for human pancreatic cancer cell lines.
Topics: Aclarubicin; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcino | 1990 |
Adjuvant mitomycin-C prolongs survival time of patients undergoing extensive en bloc resection of carcinoma of the stomach invading the adjacent organs.
Topics: Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Humans; Mitomycin; Mitomycins; Neoplasm | 1990 |
Therapeutic strategies in inflammatory breast carcinoma based on prognostic factors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Combined Modality Thera | 1990 |
Experimental studies on interactions of radiation and cancer chemotherapeutic drugs in normal tissues and a solid tumour.
Topics: Animals; Antineoplastic Agents; Bleomycin; Carcinoma; Cisplatin; Combined Modality Therapy; Cyclopho | 1986 |
Postoperative adjuvant chemotherapy inhibits early recurrence of early gastric carcinoma.
Topics: Carcinoma; Combined Modality Therapy; Drug Evaluation; Gastrectomy; Humans; Lymphatic Metastasis; Mi | 1989 |
Hypoxia enhances the lethality of mitomycin C and carboquone against human malignant tumor cells in vitro.
Topics: Azirines; Carbazilquinone; Carcinoma; Cells, Cultured; Colorectal Neoplasms; HeLa Cells; Humans; Hyp | 1989 |
Primary treatment of regional and disseminated pancreatic cancer with hexamethylmelamine, mitomycin C and 5-fluorouracil infusion.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Fluorouracil; Humans; Infusi | 1989 |
Primary treatment of carcinoma of the anus by combined radiotherapy and chemotherapy.
Topics: Adult; Aged; Anus Neoplasms; Carcinoma; Combined Modality Therapy; Female; Fluorouracil; Follow-Up S | 1989 |
Therapy of advanced gastric carcinoma. The Georgetown-Lombardi Cancer Center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Doxorubicin; Fluo | 1989 |
[Massive secondary psoriasiform dermatitis secondary to intravesical administration of mitomycin C].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Drug Eruptions; Humans; Kidney Neoplasms; | 1989 |
Antitumor activity of 7-N-(2-((2-(gamma-L-glutamylamino) ethyl) dithio) ethyl) mitomycin C (KW2149) against human tumor xenografts serially transplanted into nude mice.
Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Animals; Antineoplastic Agents; Carcinoma; Carcinoma, Int | 1989 |
Mitomycin C in advanced cervical cancer.
Topics: Adenocarcinoma; Adult; Carcinoma; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Female; Humans; M | 1987 |
Evaluation of a new drug 7-N-(p-hydroxyphenyl)-mitomycin C [KW 2083] against carcinoma of the lung by the human tumor clonogenic assay.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma; Carcinoma, Small Cell; Carcinoma, Squamous Cell; C | 1985 |
Cell kinetics and chemosensitivity of human carcinomas serially transplanted into nude mice.
Topics: Animals; Carcinoma; Cell Cycle; Cell Division; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; | 1986 |
Prognostic factors in metastatic carcinoma of unknown primary.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; | 1986 |
Overcoming mitomycin C resistance with semisynthetic derivatives.
Topics: Animals; Biotransformation; Carcinoma; Cell Line; Colonic Neoplasms; DNA; Drug Resistance; Humans; M | 1986 |
Mitomycin C associated hemolytic uremic syndrome.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Doxorubicin; Fluorouracil; Hemolyti | 1987 |
Adjuvant chemotherapy for invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Transitional Cell; Cispl | 1987 |
Management of inflammatory carcinoma of the breast with combined modality therapy including intraarterial infusion chemotherapy as an induction therapy. Long-term follow-up results of 28 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Combined M | 1988 |
Enhancement of lymphocytic SCE frequencies in patients with ovarian cancer.
Topics: Adult; Aged; Carcinoma; Cell Division; Female; Humans; In Vitro Techniques; Lymphocytes; Middle Aged | 1988 |
Intraperitoneal mitomycin C in the treatment of peritoneal carcinomatosis following second-look surgery.
Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Antigens, Tumor-Associated, Carbohydrate; Carcinoma; Combi | 1988 |
Combination chemotherapy with mitomycin-C, cisplatin, and vinblastine in the treatment of non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Bronchog | 1985 |
[Chemotherapy of carcinomatous peritonitis and carcinomatous pleuritis by using activated charcoal particle adsorbing mitomycin C (MMC-CH)--studies on the clinical trials].
Topics: Animals; Carcinoma; Charcoal; Dosage Forms; Humans; Mitomycin; Mitomycins; Peritoneal Neoplasms; Ple | 1985 |